US6459917B1 - Apparatus for access to interstitial fluid, blood, or blood plasma components - Google Patents

Apparatus for access to interstitial fluid, blood, or blood plasma components Download PDF

Info

Publication number
US6459917B1
US6459917B1 US09/575,591 US57559100A US6459917B1 US 6459917 B1 US6459917 B1 US 6459917B1 US 57559100 A US57559100 A US 57559100A US 6459917 B1 US6459917 B1 US 6459917B1
Authority
US
United States
Prior art keywords
implant
central housing
septum
disposed
filtration membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/575,591
Inventor
Ashok Gowda
Roger McNichols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/575,591 priority Critical patent/US6459917B1/en
Priority to US10/209,819 priority patent/US20020183604A1/en
Application granted granted Critical
Publication of US6459917B1 publication Critical patent/US6459917B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • A61B5/14865Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14525Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using microdialysis
    • A61B5/14528Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using microdialysis invasively
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150015Source of blood
    • A61B5/150022Source of blood for capillary blood or interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150351Caps, stoppers or lids for sealing or closing a blood collection vessel or container, e.g. a test-tube or syringe barrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150839Aesthetic features, e.g. distraction means to prevent fears of child patients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/151Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
    • A61B5/15142Devices intended for single use, i.e. disposable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6848Needles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/686Permanently implanted devices, e.g. pacemakers, other stimulators, biochips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6865Access ports
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02Access sites
    • A61M39/0247Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02Access sites
    • A61M39/0247Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0258Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for vascular access, e.g. blood stream access
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02Access sites
    • A61M39/0247Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0261Means for anchoring port to the body, or ports having a special shape or being made of a specific material to allow easy implantation/integration in the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02Access sites
    • A61M39/0247Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0276Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for introducing or removing fluids into or out of the body

Definitions

  • the invention is directed to an apparatus for intradermal implantation of a device to facilitate repeated, painless, safe, and reliable access to interstitial fluid, blood, or blood plasma for monitoring of blood borne or tissue analyte concentrations including but not limited to glucose, cholesterol, lactate, bilirubin, blood gases, ureas, creatinine, phosphates, myoglobin and hormones or delivery of drugs or other injectable agents such as chemotherapeutic agents, photosensitizing agents, hormones, vaccines, or radiological or other contrast agents.
  • the present invention is directed to a method and apparatus for analyte detection which substantially overcomes one or more of the problems due to the limitations and disadvantages of the related art. More specifically, in this aspect the present invention is directed to a transcutaneous implant, methods for implanting and using the transcutaneous implant and fluid withdrawal/delivery implements and replaceable components for use with the transcutaneous implant.
  • the transcutaneous implant includes an access component to provide a stable dermal interface, a central housing disposed within the access component, a septum disposed within the central housing, and a filtration membrane disposed at a distal end of the central housing to promote mass transfer of analyte in bodily fluid into a reservoir formed by the filtration membrane, the septum and the central housing.
  • FIG. 1A is an elevational perspective side view of the implantable access port in accordance with one embodiment of the present invention.
  • FIG. 1B is a cross-sectional view of the implantable access port shown in FIG. 1A;
  • FIG. 1C is an elevational perspective side view of the transcutaneous access component according to one embodiment of the present invention.
  • FIG. 1D is an elevational perspective side view of the advanced filtration membrane component of the present invention.
  • FIG. 1E is an elevational perspective side view of the housing component which contains safety valves and a reservoir of one embodiment of the present invention
  • FIG. 2A is a cross-sectional view of another embodiment of an implantable access port for access to the blood space in accordance with the present invention.
  • FIG. 2B is a cross-sectional view of another embodiment of the access port that includes a specially shaped filtration membrane to enhance mass transfer;
  • FIG. 2C is an elevational side view of another embodiment of the access port in which a safety stop is included within the reservoir to prevent damage to the filtration membrane and the reservoir is coated with an antibacterial agent;
  • FIG. 2D is a cross-sectional view of another embodiment of the access port of the present invention.
  • FIG. 2E is a cross-sectional view of yet another embodiment of the access port of the present invention.
  • FIG. 2F is a cross-sectional view of another embodiment of the access port of the present invention.
  • FIG. 3A illustrates a side view of the access port of the present invention which has been implanted
  • FIG. 3B illustrates a side view of the access port of the present invention which has been implanted and is in use with a device for collection or delivery of fluid;
  • FIG. 4A illustrates a side view of an implanted access port according to an embodiment that includes an external sampling stop
  • FIG. 4B illustrates insertion of a sampling device that includes a needle into the implanted access port of FIG. 4A;
  • FIG. 5A illustrates a side view of an implanted access port used in conjunction with an external analyte measurement device
  • FIG. 5B illustrates a side view of an implanted access port according to an embodiment that includes a replaceable electro-enzymatic sensor
  • FIG. 5C illustrates a side view of the replaceable sensor included in the implanted access port of FIG. 5B.
  • FIG. 5D illustrates the implantable access port and replaceable electroenzymatic sensor of FIG. 5B used in conjunction with a wristwatch style measurement device.
  • a transcutaneous implant is provided, obviating the need for puncturing the skin to obtain fluid samples.
  • the implant promotes a stable biological seal at the skin interface and prevents capsule formation and exist site infection.
  • the implant includes an advanced filtration membrane that eliminates the mass transfer problem by promoting capillary networks with transcapillary mass transfer rates high enough to ensure rapid exchange of analyte between blood and the device.
  • microporous materials allow blood vessels to grow and be maintained at the tissue-material interface and in some cases within the pores of the material. However this is not true for all porous polymer membranes, even those with similar porosities and chemistries. What influences the host response is not necessarily the chemistry of the material, but the microstructure of individual features within the material onto which host cells can attach. Materials that are microporous but contain large planar features promote an avascular host response while the same material lacking these planar features and having a more fibrous structure promote neovascularization at the tissue-material interface. Thus, in embodiments of the present invention, microporous polymers having a fibrous structure are integrated into the implanted transport membrane to reduce fibrosis and enhance neovascularization.
  • an implantable access port 1 includes three main components.
  • implantable access port 1 includes an access component 5 for providing a stable dermal interface for the transcutaneous implant.
  • implantable access port 1 uses an advanced filtration membrane 10 engineered to promote improved mass transfer between analytes in the blood and those collected by implantable access port 1 .
  • a central housing 15 with septa 20 that form self-sealing apertures and a reservoir 25 for storage of fluid prior to collection is provided.
  • Annular support members 19 are affixed to central housing 15 (or formed integrally with the central housing) to support and position septa 20 .
  • the design of the implantable access port 1 is based on providing a stable interface for the implant at an externally located site and incorporating a suitable membrane for long-term biocompatibility and filtration performance.
  • the access component 5 shown in FIG. 1C includes a flat, disc-shaped skirt 30 having a central opening 35 and an array of through holes 40 distributed around disc-shaped skirt 30 . Extending out from one side of skirt 30 in registration with the opening is an integral tubular neck 45 whose lumen 50 is in registration with the opening of skirt 30 .
  • the access component 5 including skirt 30 and neck 45 , is preferably formed of a flexible, thermally stable, biocompatible material such as flexible medical grade polyurethane, polymethyl methacrylate (PMMA).
  • PE polyethylene
  • PVC polyvinyl chloride
  • PP polypropylene
  • PDMS polydimethyl siloxane
  • EGDM ethylene glycol dimethacrylate
  • PTFE polytetrafluoroethylene
  • the entire body of the skirt 30 and neck 45 is covered by a porous covering or bed 55 of material such as polyester velour (U.S. Catheter and Instrumentation Company of Glenfalls, N.Y. Part # 600k61121).
  • the thickness of the covering 55 preferably may range from 0.01 mm to 1.5 mm, and even more preferably is about 0.1 mm.
  • the covering encourages cell infiltration and the formation of subcutaneous tissue and collagen.
  • the overall design of the access component 5 may be as set forth in U.S. Pat. No. 5,662,616, which is hereby incorporated herein by reference.
  • skirt 30 preferably has a diameter ranging from 0.2 to 4.0 cm, even more preferably about 2.5 cm.
  • the thickness of skirt 30 preferably may range from 0.05 to about 0.5 cm, and even more preferably is about 0.2 cm.
  • the central opening of skirt 30 and lumen 35 of neck 45 preferably may range from 0.1 to 3.0 cm in diameter, and even more preferably are about 0.7 cm.
  • the outer diameter of neck 45 preferably may range from 0.25 to 2.0 cm, and even more preferably is about 1.0 cm.
  • the height of the entire access component 5 preferably ranges from about 0.25 to about 2.5 cm, and even more preferably is about 1.0 cm.
  • FIG. 1D illustrates the advanced filtration membrane 10 according to one embodiment.
  • the membrane 10 is designed to allow for passive diffusion of analytes in interstitial fluid (ISF) while preventing transport of cells and larger proteins.
  • the filtration membrane 10 is preferably constructed from a polyvinylidene fluoride (PVDF) membrane 60 , although other materials may be used including, but not limited to, cellulose acetate, mixed esters of cellulose, polysulfone, polyester, polypropylene, cellulose nitrate, polycarbonate, nylon (charged and uncharged), polyethylene, and vinyl acetate ethylene copolymers.
  • PVDF membrane 60 is used to promote microachitecture-driven neovascularization 62 .
  • the surface of the PVDF membrane 60 adjacent the reservoir 25 is laminated with an ultrafiltration membrane 65 consisting of any biocompatible material with pore sizes of less than 1.0 ⁇ m.
  • the ultrafiltration membrane is constructed using a hydrogel of photopolymerized polyethylene glycol (PEG).
  • PEG photopolymerized polyethylene glycol
  • the molecular weight of the PEG membrane may range in size from 100 Da to 50 Kda or more preferably 575 Da. (Sigma Chemical).
  • the laminated filtration membranes 10 are formed by spin coating aqueous hydrogel precursor solutions on the inside of the PVDF membrane 60 (e.g., a precursor solution consisting of 23% PEG-dacrylate and 0.1% 2,2′-dimethoxy-2Diphenylacetophenone (Sigma Chemical Part # 24650-42-8), a UV-activated free radical polymerization agent).
  • aqueous hydrogel precursor solutions e.g., a precursor solution consisting of 23% PEG-dacrylate and 0.1% 2,2′-dimethoxy-2Diphenylacetophenone (Sigma Chemical Part # 24650-42-8), a UV-activated free radical polymerization agent.
  • the high viscosity of the solution and surface tension between the PVDF membrane and the precursor solution does not allow significant solution penetration into the pores of the PVDF membrane and therefore does not inhibit neovascularization.
  • the coated PVDF membrane 60 is then illuminated by UV light (e.g., 365 nm, 20 mW/cm 2 ) at a distance of approximately 1 cm until complete polymerization has taken place (typically two to ten seconds or less).
  • UV light e.g., 365 nm, 20 mW/cm 2
  • the filtration membrane 10 is then attached to the housing 15 using a medical grade adhesive (e.g., an epoxy such as Loctite # 4981).
  • the PVDF membrane 60 has a pore size ranging from 0.05 ⁇ m to 40 ⁇ m, preferably about 5 ⁇ m.
  • the thickness of the filtration membrane 10 preferably may range from 10 ⁇ m to 500 ⁇ m, and even more preferably is about 100 ⁇ m.
  • the diameter of the filtration membrane 10 preferably ranges from 0.1 to 3.0 cm in diameter, and even more preferably is about 0.7 cm.
  • the filtration membrane is designed to promote neovascularization on the tissue interfacing side while preventing cellular passage with a bioprotective layer on the device side.
  • PEG is preferable but many materials with pore sizes too small for cells to pass through may be used.
  • photopolymerized PEG is suitable but other techniques of polymerization of the PEG are acceptable, for example, thermal or chemical methods may be used to initiate polymerization of the PEG.
  • central housing 15 includes a conduit 70 with septa 20 contained within conduit 70 .
  • the distal end of conduit 70 is sealed with filtration membrane 10 .
  • the portion of conduit 70 between the top of filtration membrane 10 and the bottom of lower septum 20 form collection reservoir 25 .
  • the top of conduit 70 contains a cap 80 to prevent debris and contaminants from entering conduit 70 when implantable access port 1 is not in use.
  • cap 80 depicted in FIG. 1E is a hinged, spring-loaded cap, numerous other cap designs may be used including, without limitation, a removeable, snap-on or screw on cap.
  • the conduit 70 is preferably formed of stainless steel tubing or other rigid biocompatible material.
  • conduit 70 may be formed integrally with housing 15 , being defined by the lumen thereof.
  • the outer diameter of housing 15 may range from 0.1 to 2.0 cm, and is preferably about 0.7 cm.
  • the lumen diameter of housing 15 may range from 0.125 to 1.775 cm, and is preferably about 0.5 cm.
  • Each of septum 20 is preferably constructed of an elastic, self-sealing biocompatible material, more preferably silicone rubber and is sized to fit snugly within the lumen of conduit 70 , thus providing a liquid-tight seal between collection reservoir 25 and the upper portion of conduit 70 .
  • the thickness of the individual septum 20 preferably may range from 0.05 to 1.0 cm and more preferably is about 0.3 cm.
  • the distance between the bottom of lower septum 20 and filtration membrane 10 defines the depth of collection reservoir 25 and preferably may range from 0.05 cm to 2.0 cm and more preferably is about 0.2 cm.
  • the resulting volume of collection reservoir 25 may range from 0.6 ⁇ l to 5.0 ml and more preferably is about 40 ⁇ l.
  • FIG. 2A illustrates an alternative embodiment of an implantable access port designed to be used for filtration of blood components.
  • the implant includes a transcutaneous access component 85 with a central housing component 90 connected to an arterio-venous shunt 95 .
  • the distal end of the housing component 100 is secured to the wall of the arterio-venous shunt such that an appropriate filtration membrane 103 resides within the lumen of the arterio-venous shunt 105 . Blood flowing through the arterio-venous shunt 95 is thereby filtered by the filtration membrane 103 and fluid is subsequently collected through the housing 90 .
  • FIG. 2B illustrates a further embodiment of an implantable access port described above modified such that the filtration membrane 110 is shaped to increase the surface area and hence mass transport between the tissue space and collection reservoir of analytes in interstitial fluid, blood, or blood plasma.
  • FIG. 2C illustrates a further embodiment of the collection reservoir in which a safety stop 115 is incorporated to prevent the aspirating device such as needles or capillary tubes from damaging the filtration membrane and a coating of silver 120 is used to prevent bacterial accumulation in the collected fluid.
  • the safety stop includes apertures along its circumference to permit analyte to pass in either direction between the reservoir and the aspirating device (or an agent delivery device).
  • the aspirating or delivery device having a side opening to the fluid intake or exhaust port to avoid blockage when the tip of the aspirating or delivery device contacts the bottom of the safety stop.
  • apertures smaller than the tip of the aspirating or agent delivery device may be distributed throughout the surface of the safety stop, permitting a fluid intake or exhaust port to be located anywhere on the aspirating or agent delivery device, including on the bottom of its tip.
  • FIG. 2D is a cross-section of the implantable access port shown in FIG. 1A demonstrating alternative configurations for layers contained in the advanced filtration membrane 10 .
  • the advanced filtration membrane 10 may be composed of a discrete two-layer filtration membrane 140 . In this configuration the PVDF membrane 60 is coated with a discrete layer of PEG membrane 65 .
  • the advanced filtration membrane 10 may be composed of a partially embedded 2-layer filtration membrane 141 in which the PEG ultrafiltration membrane 65 partially penetrates a small distance into the PVDF membrane 60 .
  • the advanced filtration membrane 10 may be composed of a fully embedded 2-layer filtration membrane 142 . In this configuration the full thickness of the PEG ultrafiltration membrane 65 is contained within a thickness of the PVDF membrane 60 .
  • the advanced filtration membrane 10 may be composed of a three layer filtration membrane 143 .
  • a membrane support screen 64 is included to provide additional support to the filtration membrane 10 .
  • the membrane support screen may consist of any semi-rigid or rigid material but is preferably made using a stainless steel screen.
  • FIG. 2E is a cross-section of the implantable access port shown in FIG. 1A demonstrating alternative configurations for the housing 15 in which a replaceable septa insert 130 is incorporated.
  • the septa 20 are contained within a replaceable insert 130 .
  • the replaceable insert 130 may contain a threaded wall 135 such that once the septa 20 become worn to the point that they no longer self-seal, the user may unscrew the insert 130 and replace it with a new one.
  • the new septa insert 130 is screwed into the threaded wall of the housing until it abuts a stop wall 131 , thus allowing the inert 130 to be properly disposed within the lumen of the housing 15 (or conduit as shown in FIG. 1 E).
  • Other mechanisms for securing the replaceable insert may also be used including, without limitation, friction holds, mechanical catches and the like.
  • FIG. 2F is a cross-section of the housing 15 in which only a single self-sealing septum 20 is used. Any of the alternative embodiments may contain a single self-sealing septum 20 as opposed to the two-septum configuration as shown in FIG. 1 B.
  • implantable access port 1 is implanted so that skirt 30 of access component 5 is anchored in subcutaneous tissue 200 and neck 45 of access component 5 penetrates dermal 205 and epidermal layer 210 of the skin.
  • fibrous collagen begins to deposit in holes 40 in skirt 30 to help anchor access component 5 .
  • the velour covering 55 provides a porous, fibrous-structure bed to encourage the growth of tissue and collagen around skirt 30 to provide a biological seal with the epidermal cells which migrate and invaginate along neck 45 until they reach the covering.
  • the housing component 15 which is fixed within access component 5 , provides for collection of fluid from the body without requiring breaking the skin barrier.
  • the filtration membrane 10 attached to housing 15 allows passage of interstitial fluid, blood, or blood plasma while preventing larger cells and proteins from entering collection reservoir 25 .
  • the fluid filtered by membrane 10 and stored in collection reservoir 25 becomes the sample for analyte measurement using any applicable small volume sensor.
  • implantable access port 1 is designed to be used in conjunction with a sampling device 215 .
  • the sampling device 215 may be a needle or catheter, but is preferably a specially designed capillary tube 220 with an integral stop 225 such that it cannot be introduced far enough to damage filtration membrane 10 .
  • the sampling device 215 is passed through the self-sealing septa such that the distal end of sampling device 230 is positioned within collection reservoir 25 but does not come in contact with filtration membrane 10 . Fluid is drawn within a collection chamber of sampling device 215 by capillary action or aspirating the proximal end of sampling device 215 (e.g., by slideably withdrawing a plunger from the chamber of sampling device 215 ).
  • the implantable access port described herein may be used to deliver agents into the body.
  • agents might include, but are not limited to, drugs, hormones, chemotherapeutic agents, photosensitizing agents, vaccines, radiological, or contrast agents.
  • the agent to be administered would be placed within the collection reservoir 25 (now being used as a delivery reservoir) and the membrane 10 would be designed to allow passage of the agent into the subcutaneous fluid or blood space.
  • the implantable access port is the operation of the implantable access port to deliver insulin or for use in combination with insulin pumps.
  • the implantable access port described herein may be implanted anywhere on the body having a soft tissue layer sufficiently thick to accommodate the protrusion of the access port into the subdermal space.
  • the implant is placed on the wrist or arm area for easy patient access and may include a device or implement to cover the port such as a wrist watch interface or skin colored bandage to improve patient acceptance of the aesthetic qualities of the device.
  • the access port is preferably placed somewhere on the body which is not subject to a lot of exposure or contact such as the abdomen.
  • the implantable access port provides a method for withdrawal of body fluids without requiring breach of the skin barrier.
  • the implantable access port also provides for filtration of interstitial fluid, blood, or blood plasma resulting in a sample of fluid containing an analyte of interest. Because of its porosity and fibrous structure, the access port forms an infection-free, transcutaneous implant having a biological seal around the device. Therefore, the implant is suitable for long term use. Since the implant resides in the plane between the subcutaneous and dermal layers of tissue, subsequent removal is simple if necessary. Additionally, the access port has relatively few components and may be easily manufactured with common, readily available materials. Once implanted, the withdrawal of fluid from the body can be performed in a painless and reliable manner.
  • FIG. 4A illustrates a side view of an embodiment of an implanted access port which includes an external sampling stop 235 for providing safe access to the interstitial fluid without damaging the filtration membrane 10 .
  • the external sampling stop 235 permits a needle 217 to be used with the sampling device 215 in a safe manner.
  • the sampling device 215 is inserted into the external sampling stop 235 until a flange at the forward end of the sampling device abuts a stop wall 237 .
  • the needle 217 extends through an aperture in the stop wall 237 , passes through the self-sealing septa 20 and comes to rest with the tip located just within the reservoir 25 .
  • the needle is preferably a non-coring needle (Part No. 7165, Popper & Sons, Inc., New Hyde Park, N.Y.) to prevent coring of the self-sealing septa 20 .
  • the sampling stop 235 can be custom designed according to the needle 217 and sampling device 210 used. In one embodiment, the sampling stop is removable, for example by unplugging or unscrewing from the implant 1 , thus permitting sampling stops having various profiles and receptacle shapes to be used interchangeably. In an alternative embodiment, the sampling stop 235 forms part of the implant and is capped by an end cap as discussed above (see, for example, FIG. 1E, element 80 ).
  • FIG. 5A illustrates a side view of the implanted access port used in conjunction with an external analyte measurement device.
  • an external analyte measurement device 240 is interfaced with the sampling device 215 . This configuration allows for interstitial fluid withdrawn from the device and containing the analyte of interest to be directly communicated to an external analyte measurement device 240 .
  • FIG. 5B illustrates a side view of an implanted access port that incorporates a replaceable electro-enzymatic sensor 245 .
  • the sensor chemistry 260 is contained with the electroenzymatic sensor 245 and is placed within the reservoir 25 containing the interstitial fluid.
  • Such a sensor chemistry is described in detail by Quinn et al. (Photo-crosslinked copolymers of 2 hydroxyethyl methacrylate, poly(ethylene glycol) tetra-acrylate and ethylene dimethacrylate for improving biocompatibility of biosensors), the entire content of which is hereby incorporated by reference. In the embodiment shown in FIG.
  • FIG. 5B illustrates a close up side view of the replaceable sensor 245 .
  • the sensor 245 may also contain a fluid withdrawal port 252 that would allow the user to withdraw interstitial fluid periodically in,order to calibrate the electroenzymatic sensor 245 .
  • the sensor 245 can be removed from the access port 1 and calibrated in known standards.
  • FIG. 5D illustrates implantable access port 1 and replaceable electroenzymatic sensor 245 of FIG. 5B used in conjunction with a wristwatch style measurement display device.
  • a wristwatch style analyte measurement display device 265 may be continuously worn over implantable access port 1 and replaceable electroenzymatic sensor 245 to display continuous measurement of the analyte of interest.
  • Numerous other styles and configurations of measurement display devices may be worn over implantable access port 1 in alternative embodiments.

Abstract

A transcutaneous implant having a stable biological seal at the skin interface, obviating the need for puncturing the skin to obtain fluid samples is described. The implant includes an advanced filtration membrane to promote neovascularization which eliminates mass transfer problems by promoting the development of capillary networks with transcapillary mass transfer rates high enough to insure rapid exchange of analyte between blood and the device. Additionally the membrane provides a bioprotective layer which prevents transport of proteins and cellular components into the device.

Description

BACKGROUND OF THE INVENTION
The invention is directed to an apparatus for intradermal implantation of a device to facilitate repeated, painless, safe, and reliable access to interstitial fluid, blood, or blood plasma for monitoring of blood borne or tissue analyte concentrations including but not limited to glucose, cholesterol, lactate, bilirubin, blood gases, ureas, creatinine, phosphates, myoglobin and hormones or delivery of drugs or other injectable agents such as chemotherapeutic agents, photosensitizing agents, hormones, vaccines, or radiological or other contrast agents.
There is now a large body of evidence that intensive management of blood sugars is an effective means to slow or even prevent the progression of diabetic complications such as kidney failure, heart disease, gangrene, and blindness. The design and development of a simple apparatus for obtaining interstitial fluid, blood or blood plasma samples without breaking the skin would be a large advancement in trying to improve diabetic patient compliance for monitoring blood glucose levels.
Maintaining blood glucose concentrations near normal levels in diabetic patients can only be achieved with frequent blood glucose monitoring so that appropriate actions can be taken, such as insulin injections, or sugar ingestion. Unfortunately the current methods of sensing are based on colorimetric or electro-enzymatic approaches that require a blood or interstitial fluid sample each time a reading is needed. Withdrawal of a blood or interstitial fluid sample currently requires invasive methods of penetrating the skin surface. These methods are both time-consuming and painful and therefore there is a significant lack of compliance among the diabetic population for monitoring their blood glucose levels for the recommended five or more times daily.
Several research groups have focused efforts on methods for minimally invasive withdrawal of (primarily) interstitial fluid including the use of electrical current, suction, penetration, microdialysis, and laser-assisted drilling of the stratum corneum. While these techniques have shown some preliminary promise, questions still remain as to the volume of fluid which can be obtained, the repeatability of samples obtained, and the lack of any significant improvement in skin trauma related to the sampling methods. Additionally, the accuracy of glucose measurements on such small samples of interstitial fluid will likely be highly sensitive to contaminants from sweat or dirt on the surfaces being sampled and requires development of new measurement technology appropriate for such small or low concentration samples. Therefore, the ability to directly withdraw interstitial fluid samples in an easy, reliable and safe manner would be a significant advance in minimally invasive sensing techniques.
Other groups are developing totally implantable sensors for measurement of blood or interstitial fluid glucose concentration. Normally, however, when a foreign body such as a medical implant is introduced into a host, the natural tendency of the surrounding tissue is to degrade or extrude the implant. If the host cannot eliminate the foreign body, a chronic inflammatory reaction results and the object is encapsulated in fibrous tissue with foreign body giant cells residing at the tissue-material interface. This capsule poses a difficult problem in the development of implanted sensing or sampling devices. In the case of interstitial fluid sampling, the fibrous capsule presents a mass transfer barrier and therefore limits the concentration of analyte reaching the collection site. Also, encapsulated implants may exhibit a significant lag time in the response to changes in blood glucose concentration. The ability of the capsule to limit mass transfer has been demonstrated in several studies (see, for example, Wood et al., Assessment of a Model for Measuring Drug Diffusion Through Implant-Generated Fibrous Capsule Membranes, Biomaterials. 16:957-9, (1995)).
SUMMARY OF THE INVENTION
In one aspect, the present invention is directed to a method and apparatus for analyte detection which substantially overcomes one or more of the problems due to the limitations and disadvantages of the related art. More specifically, in this aspect the present invention is directed to a transcutaneous implant, methods for implanting and using the transcutaneous implant and fluid withdrawal/delivery implements and replaceable components for use with the transcutaneous implant. In one embodiment of this aspect of the invention, the transcutaneous implant includes an access component to provide a stable dermal interface, a central housing disposed within the access component, a septum disposed within the central housing, and a filtration membrane disposed at a distal end of the central housing to promote mass transfer of analyte in bodily fluid into a reservoir formed by the filtration membrane, the septum and the central housing.
These and other features and advantages of the present invention will be apparent from the accompanying drawings and from the detailed description and claims that follow.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention is illustrated by way of example, and not by way of limitation, in the figures of the accompanying drawings and in which like reference numerals refer to similar elements and in which:
FIG. 1A is an elevational perspective side view of the implantable access port in accordance with one embodiment of the present invention;
FIG. 1B is a cross-sectional view of the implantable access port shown in FIG. 1A;
FIG. 1C is an elevational perspective side view of the transcutaneous access component according to one embodiment of the present invention;
FIG. 1D is an elevational perspective side view of the advanced filtration membrane component of the present invention;
FIG. 1E is an elevational perspective side view of the housing component which contains safety valves and a reservoir of one embodiment of the present invention;
FIG. 2A is a cross-sectional view of another embodiment of an implantable access port for access to the blood space in accordance with the present invention;
FIG. 2B is a cross-sectional view of another embodiment of the access port that includes a specially shaped filtration membrane to enhance mass transfer;
FIG. 2C is an elevational side view of another embodiment of the access port in which a safety stop is included within the reservoir to prevent damage to the filtration membrane and the reservoir is coated with an antibacterial agent;
FIG. 2D is a cross-sectional view of another embodiment of the access port of the present invention;
FIG. 2E is a cross-sectional view of yet another embodiment of the access port of the present invention;
FIG. 2F is a cross-sectional view of another embodiment of the access port of the present invention;
FIG. 3A illustrates a side view of the access port of the present invention which has been implanted;
FIG. 3B illustrates a side view of the access port of the present invention which has been implanted and is in use with a device for collection or delivery of fluid;
FIG. 4A illustrates a side view of an implanted access port according to an embodiment that includes an external sampling stop;
FIG. 4B illustrates insertion of a sampling device that includes a needle into the implanted access port of FIG. 4A;
FIG. 5A illustrates a side view of an implanted access port used in conjunction with an external analyte measurement device;
FIG. 5B illustrates a side view of an implanted access port according to an embodiment that includes a replaceable electro-enzymatic sensor;
FIG. 5C illustrates a side view of the replaceable sensor included in the implanted access port of FIG. 5B; and
FIG. 5D illustrates the implantable access port and replaceable electroenzymatic sensor of FIG. 5B used in conjunction with a wristwatch style measurement device.
DETAILED DESCRIPTION
The invention disclosed herein eliminates many of the problems associated with prior art methods for fluid withdrawal. In one embodiment, a transcutaneous implant is provided, obviating the need for puncturing the skin to obtain fluid samples. The implant promotes a stable biological seal at the skin interface and prevents capsule formation and exist site infection. The implant includes an advanced filtration membrane that eliminates the mass transfer problem by promoting capillary networks with transcapillary mass transfer rates high enough to ensure rapid exchange of analyte between blood and the device. There are several strategies for promoting this neovascularization, including prevascularization, the release of angiogenic factors, and microarchitecture-driven neovascularization.
Certain microporous materials allow blood vessels to grow and be maintained at the tissue-material interface and in some cases within the pores of the material. However this is not true for all porous polymer membranes, even those with similar porosities and chemistries. What influences the host response is not necessarily the chemistry of the material, but the microstructure of individual features within the material onto which host cells can attach. Materials that are microporous but contain large planar features promote an avascular host response while the same material lacking these planar features and having a more fibrous structure promote neovascularization at the tissue-material interface. Thus, in embodiments of the present invention, microporous polymers having a fibrous structure are integrated into the implanted transport membrane to reduce fibrosis and enhance neovascularization.
An embodiment of the present invention is illustrated in FIGS. 1A-1E. As shown in FIGS. 1A and 1B, an implantable access port 1 includes three main components. First, implantable access port 1 includes an access component 5 for providing a stable dermal interface for the transcutaneous implant. Second, implantable access port 1 uses an advanced filtration membrane 10 engineered to promote improved mass transfer between analytes in the blood and those collected by implantable access port 1. Finally, a central housing 15 with septa 20 that form self-sealing apertures and a reservoir 25 for storage of fluid prior to collection is provided. Annular support members 19 are affixed to central housing 15 (or formed integrally with the central housing) to support and position septa 20.
Using needles, capillary tubes or other aspirating device, interstitial fluid, blood or blood plasma can be sampled from the access port 1 in a painless fashion since the skin at the exit site is effectively removed. Practice of this device by a diabetic patient would allow the patient to monitor blood glucose levels more frequently and maintain approximately normal 24-hour blood-glucose profiles thereby reducing complications related to the disease.
The preferred embodiments of this invention are described below. Alternate embodiments are listed as well. The design of the implantable access port 1 is based on providing a stable interface for the implant at an externally located site and incorporating a suitable membrane for long-term biocompatibility and filtration performance.
Access Component
The access component 5 shown in FIG. 1C includes a flat, disc-shaped skirt 30 having a central opening 35 and an array of through holes 40 distributed around disc-shaped skirt 30. Extending out from one side of skirt 30 in registration with the opening is an integral tubular neck 45 whose lumen 50 is in registration with the opening of skirt 30. The access component 5, including skirt 30 and neck 45, is preferably formed of a flexible, thermally stable, biocompatible material such as flexible medical grade polyurethane, polymethyl methacrylate (PMMA). polyethylene (PE), polyvinyl chloride (PVC), polycarbonate, polypropylene (PP) polydimethyl siloxane (PDMS), ethylene glycol dimethacrylate (EGDM), polytetrafluoroethylene PTFE), nylon or the like.
Preferably, the entire body of the skirt 30 and neck 45 is covered by a porous covering or bed 55 of material such as polyester velour (U.S. Catheter and Instrumentation Company of Glenfalls, N.Y. Part # 600k61121). In one embodiment, the thickness of the covering 55 preferably may range from 0.01 mm to 1.5 mm, and even more preferably is about 0.1 mm. The covering encourages cell infiltration and the formation of subcutaneous tissue and collagen. The overall design of the access component 5 may be as set forth in U.S. Pat. No. 5,662,616, which is hereby incorporated herein by reference.
In the present invention, skirt 30 preferably has a diameter ranging from 0.2 to 4.0 cm, even more preferably about 2.5 cm. The thickness of skirt 30 preferably may range from 0.05 to about 0.5 cm, and even more preferably is about 0.2 cm. The central opening of skirt 30 and lumen 35 of neck 45 preferably may range from 0.1 to 3.0 cm in diameter, and even more preferably are about 0.7 cm. The outer diameter of neck 45 preferably may range from 0.25 to 2.0 cm, and even more preferably is about 1.0 cm. The height of the entire access component 5 preferably ranges from about 0.25 to about 2.5 cm, and even more preferably is about 1.0 cm.
Advanced Filtration Membrane
FIG. 1D illustrates the advanced filtration membrane 10 according to one embodiment. The membrane 10 is designed to allow for passive diffusion of analytes in interstitial fluid (ISF) while preventing transport of cells and larger proteins. The filtration membrane 10 is preferably constructed from a polyvinylidene fluoride (PVDF) membrane 60, although other materials may be used including, but not limited to, cellulose acetate, mixed esters of cellulose, polysulfone, polyester, polypropylene, cellulose nitrate, polycarbonate, nylon (charged and uncharged), polyethylene, and vinyl acetate ethylene copolymers. The PVDF membrane 60 is used to promote microachitecture-driven neovascularization 62. To prevent cells from entering the collection reservoir 25, the surface of the PVDF membrane 60 adjacent the reservoir 25 is laminated with an ultrafiltration membrane 65 consisting of any biocompatible material with pore sizes of less than 1.0 μm. Preferably, the ultrafiltration membrane is constructed using a hydrogel of photopolymerized polyethylene glycol (PEG). The molecular weight of the PEG membrane may range in size from 100 Da to 50 Kda or more preferably 575 Da. (Sigma Chemical). In one embodiment, the laminated filtration membranes 10 are formed by spin coating aqueous hydrogel precursor solutions on the inside of the PVDF membrane 60 (e.g., a precursor solution consisting of 23% PEG-dacrylate and 0.1% 2,2′-dimethoxy-2Diphenylacetophenone (Sigma Chemical Part # 24650-42-8), a UV-activated free radical polymerization agent). The high viscosity of the solution and surface tension between the PVDF membrane and the precursor solution does not allow significant solution penetration into the pores of the PVDF membrane and therefore does not inhibit neovascularization. The coated PVDF membrane 60, is then illuminated by UV light (e.g., 365 nm, 20 mW/cm2) at a distance of approximately 1 cm until complete polymerization has taken place (typically two to ten seconds or less). The filtration membrane 10 is then attached to the housing 15 using a medical grade adhesive (e.g., an epoxy such as Loctite # 4981).
In one embodiment, the PVDF membrane 60 has a pore size ranging from 0.05 μm to 40 μm, preferably about 5 μm. The thickness of the filtration membrane 10 preferably may range from 10 μm to 500 μm, and even more preferably is about 100 μm. The diameter of the filtration membrane 10 preferably ranges from 0.1 to 3.0 cm in diameter, and even more preferably is about 0.7 cm.
In short, the filtration membrane is designed to promote neovascularization on the tissue interfacing side while preventing cellular passage with a bioprotective layer on the device side. As mentioned above, PEG is preferable but many materials with pore sizes too small for cells to pass through may be used. In addition, as mentioned above, photopolymerized PEG is suitable but other techniques of polymerization of the PEG are acceptable, for example, thermal or chemical methods may be used to initiate polymerization of the PEG.
Implant Housing
As depicted in FIG. 1E, central housing 15 includes a conduit 70 with septa 20 contained within conduit 70. The distal end of conduit 70 is sealed with filtration membrane 10. The portion of conduit 70 between the top of filtration membrane 10 and the bottom of lower septum 20 form collection reservoir 25. The top of conduit 70 contains a cap 80 to prevent debris and contaminants from entering conduit 70 when implantable access port 1 is not in use. Although cap 80 depicted in FIG. 1E is a hinged, spring-loaded cap, numerous other cap designs may be used including, without limitation, a removeable, snap-on or screw on cap.
The conduit 70 is preferably formed of stainless steel tubing or other rigid biocompatible material. Alternatively, conduit 70 may be formed integrally with housing 15, being defined by the lumen thereof. The outer diameter of housing 15 may range from 0.1 to 2.0 cm, and is preferably about 0.7 cm. The lumen diameter of housing 15 may range from 0.125 to 1.775 cm, and is preferably about 0.5 cm. Each of septum 20 is preferably constructed of an elastic, self-sealing biocompatible material, more preferably silicone rubber and is sized to fit snugly within the lumen of conduit 70, thus providing a liquid-tight seal between collection reservoir 25 and the upper portion of conduit 70. The thickness of the individual septum 20 preferably may range from 0.05 to 1.0 cm and more preferably is about 0.3 cm. The distance between the bottom of lower septum 20 and filtration membrane 10 defines the depth of collection reservoir 25 and preferably may range from 0.05 cm to 2.0 cm and more preferably is about 0.2 cm. The resulting volume of collection reservoir 25 may range from 0.6 μl to 5.0 ml and more preferably is about 40 μl.
FIG. 2A illustrates an alternative embodiment of an implantable access port designed to be used for filtration of blood components. The implant includes a transcutaneous access component 85 with a central housing component 90 connected to an arterio-venous shunt 95. The distal end of the housing component 100 is secured to the wall of the arterio-venous shunt such that an appropriate filtration membrane 103 resides within the lumen of the arterio-venous shunt 105. Blood flowing through the arterio-venous shunt 95 is thereby filtered by the filtration membrane 103 and fluid is subsequently collected through the housing 90.
FIG. 2B illustrates a further embodiment of an implantable access port described above modified such that the filtration membrane 110 is shaped to increase the surface area and hence mass transport between the tissue space and collection reservoir of analytes in interstitial fluid, blood, or blood plasma.
FIG. 2C illustrates a further embodiment of the collection reservoir in which a safety stop 115 is incorporated to prevent the aspirating device such as needles or capillary tubes from damaging the filtration membrane and a coating of silver 120 is used to prevent bacterial accumulation in the collected fluid. As shown in FIG. 2C, the safety stop includes apertures along its circumference to permit analyte to pass in either direction between the reservoir and the aspirating device (or an agent delivery device). Preferably, the aspirating or delivery device having a side opening to the fluid intake or exhaust port to avoid blockage when the tip of the aspirating or delivery device contacts the bottom of the safety stop. In an alternative embodiment, apertures smaller than the tip of the aspirating or agent delivery device may be distributed throughout the surface of the safety stop, permitting a fluid intake or exhaust port to be located anywhere on the aspirating or agent delivery device, including on the bottom of its tip.
FIG. 2D is a cross-section of the implantable access port shown in FIG. 1A demonstrating alternative configurations for layers contained in the advanced filtration membrane 10. The advanced filtration membrane 10 may be composed of a discrete two-layer filtration membrane 140. In this configuration the PVDF membrane 60 is coated with a discrete layer of PEG membrane 65. Alternatively the advanced filtration membrane 10 may be composed of a partially embedded 2-layer filtration membrane 141 in which the PEG ultrafiltration membrane 65 partially penetrates a small distance into the PVDF membrane 60. In another alternative, the advanced filtration membrane 10 may be composed of a fully embedded 2-layer filtration membrane 142. In this configuration the full thickness of the PEG ultrafiltration membrane 65 is contained within a thickness of the PVDF membrane 60. In yet another alternative, the advanced filtration membrane 10 may be composed of a three layer filtration membrane 143. In this configuration a membrane support screen 64 is included to provide additional support to the filtration membrane 10. The membrane support screen may consist of any semi-rigid or rigid material but is preferably made using a stainless steel screen.
FIG. 2E is a cross-section of the implantable access port shown in FIG. 1A demonstrating alternative configurations for the housing 15 in which a replaceable septa insert 130 is incorporated. In this embodiment, the septa 20 are contained within a replaceable insert 130. The replaceable insert 130 may contain a threaded wall 135 such that once the septa 20 become worn to the point that they no longer self-seal, the user may unscrew the insert 130 and replace it with a new one. The new septa insert 130 is screwed into the threaded wall of the housing until it abuts a stop wall 131, thus allowing the inert 130 to be properly disposed within the lumen of the housing 15 (or conduit as shown in FIG. 1E). Other mechanisms for securing the replaceable insert may also be used including, without limitation, friction holds, mechanical catches and the like.
FIG. 2F is a cross-section of the housing 15 in which only a single self-sealing septum 20 is used. Any of the alternative embodiments may contain a single self-sealing septum 20 as opposed to the two-septum configuration as shown in FIG. 1B.
Turning to the operation of the preferred embodiment of the present invention, referring to FIG. 3A, implantable access port 1 is implanted so that skirt 30 of access component 5 is anchored in subcutaneous tissue 200 and neck 45 of access component 5 penetrates dermal 205 and epidermal layer 210 of the skin. After implantation, fibrous collagen begins to deposit in holes 40 in skirt 30 to help anchor access component 5. The velour covering 55 provides a porous, fibrous-structure bed to encourage the growth of tissue and collagen around skirt 30 to provide a biological seal with the epidermal cells which migrate and invaginate along neck 45 until they reach the covering.
The housing component 15, which is fixed within access component 5, provides for collection of fluid from the body without requiring breaking the skin barrier. The filtration membrane 10 attached to housing 15 allows passage of interstitial fluid, blood, or blood plasma while preventing larger cells and proteins from entering collection reservoir 25. The fluid filtered by membrane 10 and stored in collection reservoir 25 becomes the sample for analyte measurement using any applicable small volume sensor.
In the preferred embodiment, as shown in FIG. 3B, implantable access port 1 is designed to be used in conjunction with a sampling device 215. The sampling device 215 may be a needle or catheter, but is preferably a specially designed capillary tube 220 with an integral stop 225 such that it cannot be introduced far enough to damage filtration membrane 10. The sampling device 215 is passed through the self-sealing septa such that the distal end of sampling device 230 is positioned within collection reservoir 25 but does not come in contact with filtration membrane 10. Fluid is drawn within a collection chamber of sampling device 215 by capillary action or aspirating the proximal end of sampling device 215 (e.g., by slideably withdrawing a plunger from the chamber of sampling device 215).
Alternatively the implantable access port described herein may be used to deliver agents into the body. Such agents might include, but are not limited to, drugs, hormones, chemotherapeutic agents, photosensitizing agents, vaccines, radiological, or contrast agents. In operation, the agent to be administered would be placed within the collection reservoir 25 (now being used as a delivery reservoir) and the membrane 10 would be designed to allow passage of the agent into the subcutaneous fluid or blood space. Of particular interest, is the operation of the implantable access port to deliver insulin or for use in combination with insulin pumps.
The implantable access port described herein may be implanted anywhere on the body having a soft tissue layer sufficiently thick to accommodate the protrusion of the access port into the subdermal space. Preferably the implant is placed on the wrist or arm area for easy patient access and may include a device or implement to cover the port such as a wrist watch interface or skin colored bandage to improve patient acceptance of the aesthetic qualities of the device. Further, for durability, the access port is preferably placed somewhere on the body which is not subject to a lot of exposure or contact such as the abdomen.
As seen from the foregoing, the implantable access port provides a method for withdrawal of body fluids without requiring breach of the skin barrier. The implantable access port also provides for filtration of interstitial fluid, blood, or blood plasma resulting in a sample of fluid containing an analyte of interest. Because of its porosity and fibrous structure, the access port forms an infection-free, transcutaneous implant having a biological seal around the device. Therefore, the implant is suitable for long term use. Since the implant resides in the plane between the subcutaneous and dermal layers of tissue, subsequent removal is simple if necessary. Additionally, the access port has relatively few components and may be easily manufactured with common, readily available materials. Once implanted, the withdrawal of fluid from the body can be performed in a painless and reliable manner.
FIG. 4A illustrates a side view of an embodiment of an implanted access port which includes an external sampling stop 235 for providing safe access to the interstitial fluid without damaging the filtration membrane 10. As shown in FIG. 4B, the external sampling stop 235 permits a needle 217 to be used with the sampling device 215 in a safe manner. The sampling device 215 is inserted into the external sampling stop 235 until a flange at the forward end of the sampling device abuts a stop wall 237. As the sampling device 215 is inserted into the sampling stop 235, the needle 217 extends through an aperture in the stop wall 237, passes through the self-sealing septa 20 and comes to rest with the tip located just within the reservoir 25. The needle is preferably a non-coring needle (Part No. 7165, Popper & Sons, Inc., New Hyde Park, N.Y.) to prevent coring of the self-sealing septa 20. The sampling stop 235 can be custom designed according to the needle 217 and sampling device 210 used. In one embodiment, the sampling stop is removable, for example by unplugging or unscrewing from the implant 1, thus permitting sampling stops having various profiles and receptacle shapes to be used interchangeably. In an alternative embodiment, the sampling stop 235 forms part of the implant and is capped by an end cap as discussed above (see, for example, FIG. 1E, element 80).
FIG. 5A illustrates a side view of the implanted access port used in conjunction with an external analyte measurement device. In this embodiment an external analyte measurement device 240 is interfaced with the sampling device 215. This configuration allows for interstitial fluid withdrawn from the device and containing the analyte of interest to be directly communicated to an external analyte measurement device 240.
FIG. 5B illustrates a side view of an implanted access port that incorporates a replaceable electro-enzymatic sensor 245. In one embodiment, the sensor chemistry 260 is contained with the electroenzymatic sensor 245 and is placed within the reservoir 25 containing the interstitial fluid. Such a sensor chemistry is described in detail by Quinn et al. (Photo-crosslinked copolymers of 2 hydroxyethyl methacrylate, poly(ethylene glycol) tetra-acrylate and ethylene dimethacrylate for improving biocompatibility of biosensors), the entire content of which is hereby incorporated by reference. In the embodiment shown in FIG. 5B, a working electrode terminal 250 and a reference electrode terminal 255 are incorporated on the replaceable sensor 245 such that they are located outside the access port 1 with electrical conductors that are connected with the sensor chemistry 260. By this arrangement, an external analyte measurement device 240 may be interfaced with the replaceable sensor 245 to provide a measurement of the analyte of interest. FIG. 5C illustrates a close up side view of the replaceable sensor 245. The sensor 245 may also contain a fluid withdrawal port 252 that would allow the user to withdraw interstitial fluid periodically in,order to calibrate the electroenzymatic sensor 245. Alternatively, the sensor 245 can be removed from the access port 1 and calibrated in known standards.
FIG. 5D illustrates implantable access port 1 and replaceable electroenzymatic sensor 245 of FIG. 5B used in conjunction with a wristwatch style measurement display device. In this embodiment, a wristwatch style analyte measurement display device 265 may be continuously worn over implantable access port 1 and replaceable electroenzymatic sensor 245 to display continuous measurement of the analyte of interest. Numerous other styles and configurations of measurement display devices may be worn over implantable access port 1 in alternative embodiments.
While the present invention has been described with reference to illustrative embodiments that include specific details, such embodiments and details should not be construed as limiting the scope of the invention. For example, though numerous preferences for shapes, materials, sizes and configurations have been described, other 20 shapes, materials, sizes and configurations may be used without departing from the spirit and scope of the present invention. Those having ordinary skill in the art and access to the teachings provided herein will recognize additional modifications, applications, and embodiments within the scope the invention described herein and additional fields in which the invention would be of significant utility without undue experimentation. Thus the scope of the invention should be determined by the appended claims and their legal equivalents, rather than by the examples given.

Claims (58)

What is claimed is:
1. A transcutaneous implant comprising:
an access component to provide a stable dermal interface;
a central housing disposed within the access component, the central housing having a first end for external access and a second end;
a first septum disposed within the central housing; and
a filtration membrane disposed at the second end of the central housing to allow analyte in bodily fluid to enter a reservoir formed by the filtration membrane, the first septum and the central housing, wherein the filtration membrane includes a first material to promote neovascularization.
2. The implant of claim 1 wherein the access component includes a neck having a first end and a second end, and skirt that extends outwardly from the second end of the neck to anchor the access component in subcutaneous tissue.
3. The implant of claim 2 wherein the central housing is formed integrally with the access component and is defined by an inner surface of the neck.
4. The implant of claim 2 wherein the central housing extends beneath the skirt of the access component and is adapted to be secured to a wall of an arterio-venous shunt such that the filtration membrane resides within the arterio-venous shunt.
5. The implant of claim 2 wherein the access component includes a porous material disposed on at least a portion of the skirt of the access component wherein the porous material encourages cell infiltration and formation of tissue.
6. The implant of claim 5 wherein the porous material includes polyester velour.
7. The implant of claim 2 wherein the skirt and neck are integrally formed of a flexible, biocompatible material.
8. The implant of claim 7 wherein the flexible biocompatible material is a member of a group of materials that includes flexible medical grade polyurethane, polymethyl methacrylate (PMMA), polyethylene (PE), polyvinyl chloride (PVC), polycarbonate, polypropylene (PP) polydimethyl siloxane (PDMS), ethylene glycol dimethacrylate (EGDM), polytetrafluoroethylene PTFE), and nylon.
9. The implant of claim 2 wherein the skirt includes recessed regions containing a material that encourages growth of fibrous collagen, wherein the fibrous collagen promotes a stable seal between the access component and the skin.
10. The implant of claim 1 wherein the filtration membrane includes a material that allows passive diffusion of the analyte in the bodily fluid and substantially prevents transport of cells or larger proteins.
11. The implant of claim 1 wherein the first material is at least one of cellulose acetate, mixed esters of cellulose, polysulfone, polyester, polypropylene, cellulose nitrate, polycarbonate nylon, polyethylene, and vinyl acetate ethylene copolymers.
12. The implant of claim 1 wherein the first material includes polyvinylidene fluoride (PVDF).
13. The implant of claim 1 wherein the filtration membrane further includes a second material which allows passive diffusion of the analyte in the bodily fluid and substantially prevents transport of cells or larger proteins.
14. The implant of claim 13 wherein the second material includes polymerized polyethylene glycol (PEG).
15. The implant of claim 13 wherein the second material is laminated on the first material to form a two-layer filtration membrane.
16. The implant of claim 13 wherein a portion of the second material penetrates into the first material to form a partially embedded two-layer filtration membrane.
17. The implant of claim 13 wherein the second material is contained within a layer of the first material to form an embedded two-layer filtration membrane.
18. The implant of claim 13 wherein the filtration membrane further includes a third material, which is more rigid than at least one of the first material and the second material, to provide support to the filtration membrane.
19. The implant of claim 1 wherein the first material has a pore size ranging from 0.05 μm to 40 μm.
20. The implant of claim 1 wherein the first septum forms a liquid-tight seal between the reservoir and a side of the first septum nearest the first end of the central housing.
21. The implant of claim 20 wherein the first septum is formed of a self-sealing material such that, after the first septum has been penetrated by a fluid sampling/delivery device and the fluid sampling/delivery device removed, the first septum self-seals to reestablish the liquid-tight seal.
22. The implant of claim 21 wherein the first septum is formed from a material that includes silicone rubber.
23. The implant of claim 1 wherein the central housing includes a conduit disposed within the lumen of the central housing and wherein the first septum is disposed within the conduit and the filtration membrane is disposed at an end of the conduit adjacent the second end of the central housing.
24. The implant of claim 23 wherein the conduit is formed integrally with the central housing, the conduit being defined by an inner surface of the central housing.
25. The implant of claim 23 wherein the conduit is formed of a rigid biocompatible material.
26. The implant of claim 23 further comprising a cap disposed over an end of the conduit adjacent the first end of the central housing.
27. The implant of claim 23 further comprising a second septum disposed within the conduit nearer the first end of the central housing than the first septum, the first and second septa defining a chamber within the conduit.
28. The implant of claim 23 further comprising a support member disposed within the conduit to support the first septum, the first septum being disposed within the conduit adjacent the support member.
29. The implant of claim 1 further comprising a cap disposed over the first end of the central housing.
30. The implant of claim 1 further comprising a second septum disposed within the central housing nearer the first end than the first septum, the first and second septa defining a chamber within the central housing.
31. The implant of claim 30 where in the second septum forms a liquid-tight seal between the chamber and a side of the second septum nearest the first end of the central housing.
32. The implant of claim 1 wherein the filtration membrane is attached to the central housing using a medical grade adhesive.
33. The implant of claim 1 wherein the filtration membrane extends outwardly to form a surface area that exceeds an area of a cross section of the second end of the central housing.
34. The implant of claim 1 further comprising a safety stop to prevent a fluid sampling/delivery device from contacting the filtration membrane.
35. The implant of claim 34 wherein the safety stop is disposed within the reservoir, the safety stop including an aperture to permit the analyte to pass between the reservoir and the fluid sampling/delivery device.
36. The implant of claim 1 wherein at least a portion of the reservoir is lined with an antibacterial coating.
37. The implant of claim 36 wherein the antibacterial coating includes silver.
38. The implant of claim 1 wherein the first septum is removable from the central housing to allow replacement thereof.
39. The implant of claim 1 further comprising a sampling stop disposed at the first end of the central housing to limit the insertion of a fluid sampling/delivery device such that the device is prevented from contacting the filtration membrane.
40. The implant of claim 39 wherein the sampling stop includes a stop wall adapted to engage a flange of the fluid sampling/delivery device, the stop wall including an aperture to receive a narrower portion of the fluid sampling/delivery device such that a tip of the narrower portion of the fluid sampling/delivery device rests within the reservoir when the flange of the fluid sampling/delivery device engages the stop wall.
41. The implant of claim 39 wherein the sampling stop is removable from the implant.
42. The implant of claim 1 wherein the central housing is adapted to engage an analyte measurement device and fluid sampling device such that the analyte in the reservoir is communicated to the analyte measurement device via the fluid sampling device and measured by the analyte measurement device while the analyte measurement device and fluid sampling device are engaged by the central housing.
43. A sensing system having a transcutaneous implant device comprising:
an electroenzymatic sensor;
a transcutaneous implant device, including:
an access component to provide a stable dermal interface;
a central housing disposed within the access component, the central housing having a first end for external access and a second end;
a first septum disposed within the central housing; and
a filtration membrane disposed at the second end of the central housing to allow analyte in bodily fluid to enter a reservoir formed by the filtration membrane, the first septum and the central housing, wherein the filtration membrane includes a first material to promote neovascularization.
44. The sensing system of claim 43 wherein the electroenzymatic sensor includes a chemical sensor disposed within the reservoir and first and second terminals disposed adjacent the first end of the central housing and coupled to the chemical sensor via respective electrical conductors.
45. The sensing system of claim 43 wherein the electroenzymatic sensor further includes a fluid withdrawal port to allow periodic withdrawal of the analyte.
46. The sensing system of claim 43 wherein the electroenzymatic sensor is removable.
47. The sensing system of claim 43 further comprising a display device coupled adjacent the first end of the central housing, the display device cooperating with the electroenzymatic sensor to display a measure of the analyte.
48. The sensing system of claim 47 wherein the display device is a wristwatch style device.
49. An implant to deliver fluid to, withdraw fluid from, or monitor a fluid of an animal body, the implant comprising:
an access component to provide a stable dermal interface wherein the access, component includes a housing having a first end which is externally accessible, capable of being without puncturing the skin of the animal body and a second end;
a septum, disposed within the housing, to provide a liquid tight seal; and
a membrane disposed at, and coupled to the second end of the housing wherein the membrane includes a first material that promotes neovascularization when located within the animal body and wherein the membrane, the septum and the housing form a reservoir.
50. The implant of claim 49 wherein the first material is at least one of cellulose acetate, mixed esters of cellulose, polysulfone, polyester, polypropylene, cellulose nitrate, polycarbonate nylon, polyethylene, and vinyl acetate ethylene copolymers.
51. The implant of claim 49 wherein the membrane further includes a second material which allows fluid to diffuse therethrough and substantially prevents cells from entering the reservoir.
52. The implant of claim 51 wherein the second material is laminated onto the first material to form a two-layer membrane.
53. The implant of claim 51 wherein the second material is contained within a layer of the first material to form an embedded two-layer membrane.
54. The implant of claim 51 wherein the first material includes a pore size ranging from 0.05 μm to 40 μm.
55. The implant of claim 51 further including a safety stop to prevent a fluid sampling/delivery device from contacting the membrane.
56. An implant to deliver fluid to, withdraw fluid from, or monitor a fluid of an animal body, the implant comprising:
an access component to provide a stable dermal interface wherein the access component includes a housing having a first end which is externally capable of accessible without puncturing the skin of the animal body and a second end;
a septum, disposed within the housing, to provide a liquid tight seal; and
a membrane disposed at, and coupled to the second end of the housing wherein the membrane includes a first material that retards avascularization when located within the animal body and wherein the membrane, the septum and the housing form a reservoir.
57. The implant of claim 56 wherein the first material includes a pore size ranging from 0.05 μm to 40 μm.
58. The implant of claim 57 wherein the membrane further includes a second material which allows fluid to diffuse therethrough and substantially prevents cells from entering the reservoir.
US09/575,591 2000-05-22 2000-05-22 Apparatus for access to interstitial fluid, blood, or blood plasma components Expired - Fee Related US6459917B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/575,591 US6459917B1 (en) 2000-05-22 2000-05-22 Apparatus for access to interstitial fluid, blood, or blood plasma components
US10/209,819 US20020183604A1 (en) 2000-05-22 2002-07-31 Apparatus for access to interstitial fluid, blood, or blood plasma components

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/575,591 US6459917B1 (en) 2000-05-22 2000-05-22 Apparatus for access to interstitial fluid, blood, or blood plasma components

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/209,819 Division US20020183604A1 (en) 2000-05-22 2002-07-31 Apparatus for access to interstitial fluid, blood, or blood plasma components

Publications (1)

Publication Number Publication Date
US6459917B1 true US6459917B1 (en) 2002-10-01

Family

ID=24300921

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/575,591 Expired - Fee Related US6459917B1 (en) 2000-05-22 2000-05-22 Apparatus for access to interstitial fluid, blood, or blood plasma components
US10/209,819 Abandoned US20020183604A1 (en) 2000-05-22 2002-07-31 Apparatus for access to interstitial fluid, blood, or blood plasma components

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/209,819 Abandoned US20020183604A1 (en) 2000-05-22 2002-07-31 Apparatus for access to interstitial fluid, blood, or blood plasma components

Country Status (1)

Country Link
US (2) US6459917B1 (en)

Cited By (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123676A1 (en) * 1999-09-08 2002-09-05 Ulrich Haueter Measuring device for body fluids and infusion set and dialysis probe comprising such a measuring device one
US20030018362A1 (en) * 2001-06-15 2003-01-23 Chris Fellows Ablation stent for treating atrial fibrillation
WO2003049592A3 (en) * 2001-06-29 2003-07-31 Philometron Inc Gateway platform for biological monitoring and delivery of therapeutic compounds
US6614521B2 (en) * 1999-08-31 2003-09-02 Cme Telemetrix Inc. Device for verifying the accuracy of a spectral analyzer
US20030220552A1 (en) * 1999-07-01 2003-11-27 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US20050004526A1 (en) * 2001-08-31 2005-01-06 Andreas Reinemann Implant with surface structure
US20050197653A1 (en) * 2004-03-02 2005-09-08 Sniegowski Jeffry J. Filter assembly with microfabricated filter element
US20050251083A1 (en) * 2004-02-12 2005-11-10 Victoria Carr-Brendel Biointerface with macro-and micro-architecture
US6986755B2 (en) * 1998-05-20 2006-01-17 Disetronic Licensing Ag Sensor system including port body
US20060020192A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060030790A1 (en) * 2004-08-06 2006-02-09 Braig James R Sample element with barrier material and vacuum
US20060041318A1 (en) * 2004-08-19 2006-02-23 Shannon Donald T Laminar skin-bone fixation transcutaneous implant and method for use thereof
US20070006820A1 (en) * 2005-07-06 2007-01-11 Steven Denault Harness interface conduit, tether line, and swivel for use in animals
US7236821B2 (en) 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
US20090157014A1 (en) * 2007-12-17 2009-06-18 William Cook Europe Aps Device for enabling repeated access to a vessel
US20090205647A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Pneumostoma management system having a cosmetic and/or protective cover
US7711402B2 (en) 1997-03-04 2010-05-04 Dexcom, Inc. Device and method for determining analyte levels
US7761130B2 (en) 2003-07-25 2010-07-20 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7771352B2 (en) 1997-03-04 2010-08-10 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US7831287B2 (en) 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7828711B2 (en) 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
US7860544B2 (en) 1998-04-30 2010-12-28 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US7860545B2 (en) 1997-03-04 2010-12-28 Dexcom, Inc. Analyte measuring device
US7875293B2 (en) 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US7881763B2 (en) 2003-04-04 2011-02-01 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US20110038903A1 (en) * 2009-08-17 2011-02-17 Singh Ashok K Apparatus and Process for Generating and Harvesting Adult Stem Cells and Fluid Associated with it from Skin and Omentum for Medical, Cosmetic, and Veterinary Use
US7905833B2 (en) 2004-07-13 2011-03-15 Dexcom, Inc. Transcutaneous analyte sensor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US7976778B2 (en) 2001-04-02 2011-07-12 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8000901B2 (en) 2003-08-01 2011-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US8016783B2 (en) 2003-08-21 2011-09-13 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
US8050731B2 (en) 2002-05-22 2011-11-01 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US8052601B2 (en) 2003-08-01 2011-11-08 Dexcom, Inc. System and methods for processing analyte sensor data
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US8064977B2 (en) 2002-05-22 2011-11-22 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US8118877B2 (en) 2003-05-21 2012-02-21 Dexcom, Inc. Porous membranes for use with implantable devices
US20120053562A1 (en) * 2010-08-25 2012-03-01 Medtronic, Inc. Fluid delivery device refill access
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US8160671B2 (en) 2003-12-05 2012-04-17 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
USRE43399E1 (en) 2003-07-25 2012-05-22 Dexcom, Inc. Electrode systems for electrochemical sensors
US8275456B2 (en) 2002-11-12 2012-09-25 Cardiac Pacemakers, Inc. Implantable device for delivering cardiac drug therapy
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8280475B2 (en) 2004-07-13 2012-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8287454B2 (en) 1998-04-30 2012-10-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20120281218A1 (en) * 2005-01-24 2012-11-08 The Board Of Trustees Of The Leland Stanford Junior University Optical analysis system and approach therefor
US20120289795A1 (en) * 2009-11-16 2012-11-15 Maquet Critical Care Ab Self-Flowing Measuring System
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20130018248A1 (en) * 2011-07-12 2013-01-17 Romedex International Srl Devices and methods for ECG guided vascular access
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US20130066171A1 (en) * 2010-05-06 2013-03-14 Roche Diagnostics Operations, Inc. Lancet Magazine and Method for the Production Thereof
US8398654B2 (en) 2008-04-17 2013-03-19 Allergan, Inc. Implantable access port device and attachment system
CN103002942A (en) * 2010-07-02 2013-03-27 日机装株式会社 Artificial blood vessel and access port of artificial blood vessel
US8409221B2 (en) 2008-04-17 2013-04-02 Allergan, Inc. Implantable access port device having a safety cap
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8509871B2 (en) 2001-07-27 2013-08-13 Dexcom, Inc. Sensor head for use with implantable devices
US8506532B2 (en) 2009-08-26 2013-08-13 Allergan, Inc. System including access port and applicator tool
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US8562558B2 (en) 2007-06-08 2013-10-22 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8612159B2 (en) 1998-04-30 2013-12-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8622905B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. System and methods for processing analyte sensor data
US8652043B2 (en) 2001-01-02 2014-02-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8660648B2 (en) 2005-10-24 2014-02-25 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8690769B2 (en) 2008-04-21 2014-04-08 Philometron, Inc. Metabolic energy monitoring system
US8708979B2 (en) 2009-08-26 2014-04-29 Apollo Endosurgery, Inc. Implantable coupling device
US8715158B2 (en) 2009-08-26 2014-05-06 Apollo Endosurgery, Inc. Implantable bottom exit port
US8792955B2 (en) 2004-05-03 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US8805492B2 (en) 2004-08-20 2014-08-12 Cardiac Pacemakers, Inc. Method and apparatus for delivering combined electrical and drug therapies
US8801597B2 (en) 2011-08-25 2014-08-12 Apollo Endosurgery, Inc. Implantable access port with mesh attachment rivets
US8821373B2 (en) 2011-05-10 2014-09-02 Apollo Endosurgery, Inc. Directionless (orientation independent) needle injection port
US8840552B2 (en) 2001-07-27 2014-09-23 Dexcom, Inc. Membrane for use with implantable devices
US8858421B2 (en) 2011-11-15 2014-10-14 Apollo Endosurgery, Inc. Interior needle stick guard stems for tubes
US8882728B2 (en) 2010-02-10 2014-11-11 Apollo Endosurgery, Inc. Implantable injection port
US8882655B2 (en) 2010-09-14 2014-11-11 Apollo Endosurgery, Inc. Implantable access port system
US8905916B2 (en) 2010-08-16 2014-12-09 Apollo Endosurgery, Inc. Implantable access port system
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8992415B2 (en) 2010-04-30 2015-03-31 Apollo Endosurgery, Inc. Implantable device to protect tubing from puncture
US20150157836A1 (en) * 2008-01-28 2015-06-11 Peter Mats Forsell Implantable drainage device
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9075910B2 (en) 2010-03-11 2015-07-07 Philometron, Inc. Physiological monitor system for determining medication delivery and outcome
US9089395B2 (en) 2011-11-16 2015-07-28 Appolo Endosurgery, Inc. Pre-loaded septum for use with an access port
US9125718B2 (en) 2010-04-30 2015-09-08 Apollo Endosurgery, Inc. Electronically enhanced access port for a fluid filled implant
US20150266026A1 (en) * 2014-03-18 2015-09-24 Sony Corporation Plate-like member for pipette tips, pipette tip, liquid agitation kit and liquid agitation apparatus
US9155496B2 (en) 1997-03-04 2015-10-13 Dexcom, Inc. Low oxygen in vivo analyte sensor
US20150297873A1 (en) * 2012-08-22 2015-10-22 Clemson University Research Foundation Percutaneous tube stabilization device
US9192501B2 (en) 2010-04-30 2015-11-24 Apollo Endosurgery, Inc. Remotely powered remotely adjustable gastric band system
US9199069B2 (en) 2011-10-20 2015-12-01 Apollo Endosurgery, Inc. Implantable injection port
US20160022180A1 (en) * 2014-07-24 2016-01-28 Thomas Jefferson University Long-term implantable monitoring system & methods of use
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US9451908B2 (en) 2006-10-04 2016-09-27 Dexcom, Inc. Analyte sensor
US9451910B2 (en) 2007-09-13 2016-09-27 Dexcom, Inc. Transcutaneous analyte sensor
US20170036006A1 (en) * 2014-04-10 2017-02-09 University Health Network Cannula for connecting medical devices to biological systems
US9737660B2 (en) 2010-08-25 2017-08-22 Medtronic, Inc. Drug infusion device with controllable valve
US9757061B2 (en) 2006-01-17 2017-09-12 Dexcom, Inc. Low oxygen in vivo analyte sensor
US9763609B2 (en) 2003-07-25 2017-09-19 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US20180214059A1 (en) * 2008-05-30 2018-08-02 Intuity Medical, Inc. Body fluid sampling device - sampling site interface
US10463845B2 (en) 2013-01-23 2019-11-05 C.R. Bard, Inc. Low-profile access port
USD870264S1 (en) 2017-09-06 2019-12-17 C. R. Bard, Inc. Implantable apheresis port
US10791928B2 (en) 2007-05-18 2020-10-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US10835672B2 (en) 2004-02-26 2020-11-17 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
CN112040839A (en) * 2018-02-09 2020-12-04 W.L.戈尔及同仁股份有限公司 Implantable access chamber and associated methods of use
EP3760273A1 (en) * 2019-07-02 2021-01-06 SeraIP AG Implantable skin penetration device
US10966609B2 (en) 2004-02-26 2021-04-06 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11246990B2 (en) 2004-02-26 2022-02-15 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11382539B2 (en) 2006-10-04 2022-07-12 Dexcom, Inc. Analyte sensor
US11420033B2 (en) 2013-01-23 2022-08-23 C. R. Bard, Inc. Low-profile single and dual vascular access device
US11464960B2 (en) 2013-01-23 2022-10-11 C. R. Bard, Inc. Low-profile single and dual vascular access device
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US8165651B2 (en) * 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US20050240155A1 (en) * 2004-04-27 2005-10-27 Conlon Sean P Surgically implantable injection port having a centered catheter connection tube
US7727147B1 (en) * 2004-05-14 2010-06-01 Flint Hills Scientific Llc Method and system for implantable glucose monitoring and control of a glycemic state of a subject
US8224414B2 (en) * 2004-10-28 2012-07-17 Echo Therapeutics, Inc. System and method for analyte sampling and analysis with hydrogel
US7985199B2 (en) * 2005-03-17 2011-07-26 Unomedical A/S Gateway system
WO2007130724A2 (en) * 2006-02-06 2007-11-15 Northwind Ventures Systems and methods for volume reduction
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US20080199894A1 (en) 2007-02-15 2008-08-21 Abbott Diabetes Care, Inc. Device and method for automatic data acquisition and/or detection
EP3533387A3 (en) 2007-06-21 2019-11-13 Abbott Diabetes Care, Inc. Health management devices and methods
CA2690870C (en) 2007-06-21 2017-07-11 Abbott Diabetes Care Inc. Health monitor
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
WO2010138856A1 (en) 2009-05-29 2010-12-02 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
AU2010286917B2 (en) 2009-08-31 2016-03-10 Abbott Diabetes Care Inc. Medical devices and methods
EP2493417B1 (en) 2009-10-26 2017-06-21 Cardiokinetix, Inc. Ventricular volume reduction
EP3583901A3 (en) 2011-02-28 2020-01-15 Abbott Diabetes Care, Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US9069536B2 (en) 2011-10-31 2015-06-30 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
EP2859911A1 (en) * 2013-10-11 2015-04-15 qSTAR Medical SAS Vascular access port devices with incorporated sensors
WO2015102745A1 (en) 2013-12-31 2015-07-09 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
BR112017006248A2 (en) 2014-09-28 2017-12-12 Cardiokinetix Inc heart failure treatment apparatus
EP3243549A1 (en) * 2016-05-12 2017-11-15 Renishaw plc Percutaneous access apparatus
US10898330B2 (en) 2017-03-28 2021-01-26 Edwards Lifesciences Corporation Positioning, deploying, and retrieving implantable devices
WO2019195353A1 (en) * 2018-04-04 2019-10-10 Sainess Marius Low profile self-sealing access port

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3638649A (en) 1969-07-07 1972-02-01 Univ Minnesota Implantable prosthetic pass-through device
US3663965A (en) 1970-06-08 1972-05-23 Henry L Lee Jr Bacteria-resistant percutaneous conduit device
US3783868A (en) * 1971-05-06 1974-01-08 Gulf Oil Corp Percutaneous implant
US3991756A (en) 1975-08-18 1976-11-16 Donald Synder Method and apparatus for intravenous access
US4402694A (en) 1981-07-16 1983-09-06 Biotek, Inc. Body cavity access device containing a hormone source
US4633878A (en) 1983-04-18 1987-01-06 Guiseppe Bombardieri Device for the automatic insulin or glucose infusion in diabetic subjects, based on the continuous monitoring of the patient's glucose, obtained without blood withdrawal
US4777953A (en) 1987-02-25 1988-10-18 Ash Medical Systems, Inc. Capillary filtration and collection method for long-term monitoring of blood constituents
US4810246A (en) * 1987-11-04 1989-03-07 L. Vad Technology, Inc. Disposable cell culture chamber with remote access
US4854322A (en) 1987-02-25 1989-08-08 Ash Medical Systems, Inc. Capillary filtration and collection device for long-term monitoring of blood constituents
US4886501A (en) 1987-08-25 1989-12-12 Shiley Infusaid Inc. Implantable device
US4886502A (en) 1986-12-09 1989-12-12 Thermedics, Inc. Peritoneal access catheter
US4955861A (en) * 1988-04-21 1990-09-11 Therex Corp. Dual access infusion and monitoring system
US5001054A (en) 1986-06-26 1991-03-19 Becton, Dickinson And Company Method for monitoring glucose
US5035711A (en) * 1983-03-24 1991-07-30 Kabushiki Kaisya Advance Kaihatsu Kenkyujo Transcutaneously implantable element
US5161532A (en) 1990-04-19 1992-11-10 Teknekron Sensor Development Corporation Integral interstitial fluid sensor
US5242415A (en) 1992-08-14 1993-09-07 L-Vad Technology, Inc. Percutaneous access device
US5568806A (en) 1995-02-16 1996-10-29 Minimed Inc. Transcutaneous sensor insertion set
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5617851A (en) 1992-10-14 1997-04-08 Endodermic Medical Technologies Company Ultrasonic transdermal system for withdrawing fluid from an organism and determining the concentration of a substance in the fluid
US5662616A (en) 1995-07-07 1997-09-02 Bousquet; Gerald G. Transcutaneous access device
US5706807A (en) 1991-05-13 1998-01-13 Applied Medical Research Sensor device covered with foam membrane
US5722397A (en) * 1993-11-15 1998-03-03 Altea Technologies, Inc. Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5833655A (en) * 1997-05-15 1998-11-10 L. Vad Technology, Inc. Percutaneous access device having removable turret assembly
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5913833A (en) 1997-02-07 1999-06-22 Abbott Laboratories Method and apparatus for obtaining biological fluids
US5964804A (en) * 1990-10-31 1999-10-12 Baxter International Inc. Close vascularization implant material
US6099508A (en) * 1995-07-07 2000-08-08 Bousquet; Gerald G. Transcutaneous access device
US6122536A (en) 1995-07-06 2000-09-19 Animas Corporation Implantable sensor and system for measurement and control of blood constituent levels

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683965A (en) * 1970-04-08 1972-08-15 Materials Technology Corp Adjustable choke valve
DE4433145A1 (en) * 1994-09-17 1996-03-21 Harry Frey Magnetic door seal
US5588808A (en) * 1994-12-08 1996-12-31 Hytech Pumps International, Inc. Pump pressure multiplier

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3638649A (en) 1969-07-07 1972-02-01 Univ Minnesota Implantable prosthetic pass-through device
US3663965A (en) 1970-06-08 1972-05-23 Henry L Lee Jr Bacteria-resistant percutaneous conduit device
US3783868A (en) * 1971-05-06 1974-01-08 Gulf Oil Corp Percutaneous implant
US3991756A (en) 1975-08-18 1976-11-16 Donald Synder Method and apparatus for intravenous access
US4402694A (en) 1981-07-16 1983-09-06 Biotek, Inc. Body cavity access device containing a hormone source
US5035711A (en) * 1983-03-24 1991-07-30 Kabushiki Kaisya Advance Kaihatsu Kenkyujo Transcutaneously implantable element
US4633878A (en) 1983-04-18 1987-01-06 Guiseppe Bombardieri Device for the automatic insulin or glucose infusion in diabetic subjects, based on the continuous monitoring of the patient's glucose, obtained without blood withdrawal
US5001054A (en) 1986-06-26 1991-03-19 Becton, Dickinson And Company Method for monitoring glucose
US4886502A (en) 1986-12-09 1989-12-12 Thermedics, Inc. Peritoneal access catheter
US4777953A (en) 1987-02-25 1988-10-18 Ash Medical Systems, Inc. Capillary filtration and collection method for long-term monitoring of blood constituents
US4854322A (en) 1987-02-25 1989-08-08 Ash Medical Systems, Inc. Capillary filtration and collection device for long-term monitoring of blood constituents
US4886501A (en) 1987-08-25 1989-12-12 Shiley Infusaid Inc. Implantable device
US4810246A (en) * 1987-11-04 1989-03-07 L. Vad Technology, Inc. Disposable cell culture chamber with remote access
US4955861A (en) * 1988-04-21 1990-09-11 Therex Corp. Dual access infusion and monitoring system
US5161532A (en) 1990-04-19 1992-11-10 Teknekron Sensor Development Corporation Integral interstitial fluid sensor
US5964804A (en) * 1990-10-31 1999-10-12 Baxter International Inc. Close vascularization implant material
US5706807A (en) 1991-05-13 1998-01-13 Applied Medical Research Sensor device covered with foam membrane
US5242415A (en) 1992-08-14 1993-09-07 L-Vad Technology, Inc. Percutaneous access device
US5617851A (en) 1992-10-14 1997-04-08 Endodermic Medical Technologies Company Ultrasonic transdermal system for withdrawing fluid from an organism and determining the concentration of a substance in the fluid
US5746217A (en) 1993-10-13 1998-05-05 Integ Incorporated Interstitial fluid collection and constituent measurement
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5820570A (en) 1993-10-13 1998-10-13 Integ Incorporated Interstitial fluid collection and constituent measurement
US5722397A (en) * 1993-11-15 1998-03-03 Altea Technologies, Inc. Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5568806A (en) 1995-02-16 1996-10-29 Minimed Inc. Transcutaneous sensor insertion set
US6122536A (en) 1995-07-06 2000-09-19 Animas Corporation Implantable sensor and system for measurement and control of blood constituent levels
US5662616A (en) 1995-07-07 1997-09-02 Bousquet; Gerald G. Transcutaneous access device
US6099508A (en) * 1995-07-07 2000-08-08 Bousquet; Gerald G. Transcutaneous access device
US5913833A (en) 1997-02-07 1999-06-22 Abbott Laboratories Method and apparatus for obtaining biological fluids
US5833655A (en) * 1997-05-15 1998-11-10 L. Vad Technology, Inc. Percutaneous access device having removable turret assembly

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Dasse et al., "A polyurethane percutaneous access device for peritoneal dialysis, Advances in Peritoneal Dialysis", 1988, 4: 245-252.
Kayashima et al., "New Noninvasive Transcutaneous Approach to Blood Glucose Monitoring: Successful Glucose Monitoring on Human 75 g OGTT with Novel Sampling Chamber" IEEE Trans. On Biomed. Eng., 1991, vol. 38(8), pp. 752-757.
Padera, R. et al., "Time Course of Membrane Microarchitecture-driven Neovascularization", Biomaterials Journal, 1996, 17(3):277-84.
Petersen et al., "Microdialysis of the Interstitial Water Space in Human Skin In Vivo: Ouantitiative Measurement of Cutaneous Glucose Concentrations", Journal of Investigative Dermatology, 1992: 99-357-360.
Wood et al., "Assessment of a Model for Measuring Drug Diffusion Through Implant-Generated Fibrous Capsule Membranes", Biomaterials Journal, 1995, 16:957-9.

Cited By (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7711402B2 (en) 1997-03-04 2010-05-04 Dexcom, Inc. Device and method for determining analyte levels
US9155496B2 (en) 1997-03-04 2015-10-13 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7901354B2 (en) 1997-03-04 2011-03-08 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7860545B2 (en) 1997-03-04 2010-12-28 Dexcom, Inc. Analyte measuring device
US7771352B2 (en) 1997-03-04 2010-08-10 Dexcom, Inc. Low oxygen in vivo analyte sensor
US8670815B2 (en) 1998-04-30 2014-03-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8734348B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10478108B2 (en) 1998-04-30 2019-11-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9326714B2 (en) 1998-04-30 2016-05-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9072477B2 (en) 1998-04-30 2015-07-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066694B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066697B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9042953B2 (en) 1998-04-30 2015-05-26 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9014773B2 (en) 1998-04-30 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9011331B2 (en) 1998-04-30 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8880137B2 (en) 1998-04-30 2014-11-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8840553B2 (en) 1998-04-30 2014-09-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8774887B2 (en) 1998-04-30 2014-07-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8744545B2 (en) 1998-04-30 2014-06-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8734346B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8738109B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8672844B2 (en) 1998-04-30 2014-03-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8666469B2 (en) 1998-04-30 2014-03-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8660627B2 (en) 1998-04-30 2014-02-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8649841B2 (en) 1998-04-30 2014-02-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8641619B2 (en) 1998-04-30 2014-02-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8622906B2 (en) 1998-04-30 2014-01-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8617071B2 (en) 1998-04-30 2013-12-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8612159B2 (en) 1998-04-30 2013-12-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8597189B2 (en) 1998-04-30 2013-12-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8473021B2 (en) 1998-04-30 2013-06-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US7860544B2 (en) 1998-04-30 2010-12-28 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8409131B2 (en) 1998-04-30 2013-04-02 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US7869853B1 (en) 1998-04-30 2011-01-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8391945B2 (en) 1998-04-30 2013-03-05 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8380273B2 (en) 1998-04-30 2013-02-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US7885699B2 (en) 1998-04-30 2011-02-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8372005B2 (en) 1998-04-30 2013-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8366614B2 (en) 1998-04-30 2013-02-05 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8357091B2 (en) 1998-04-30 2013-01-22 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8353829B2 (en) 1998-04-30 2013-01-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346336B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8306598B2 (en) 1998-04-30 2012-11-06 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8287454B2 (en) 1998-04-30 2012-10-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8273022B2 (en) 1998-04-30 2012-09-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8275439B2 (en) 1998-04-30 2012-09-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8265726B2 (en) 1998-04-30 2012-09-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8260392B2 (en) 1998-04-30 2012-09-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8255031B2 (en) 1998-04-30 2012-08-28 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8235896B2 (en) 1998-04-30 2012-08-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8231532B2 (en) 1998-04-30 2012-07-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226555B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226557B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226558B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8224413B2 (en) 1998-04-30 2012-07-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8177716B2 (en) 1998-04-30 2012-05-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8175673B2 (en) 1998-04-30 2012-05-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8162829B2 (en) 1998-04-30 2012-04-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6986755B2 (en) * 1998-05-20 2006-01-17 Disetronic Licensing Ag Sensor system including port body
US7166074B2 (en) * 1999-07-01 2007-01-23 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US20030220552A1 (en) * 1999-07-01 2003-11-27 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US20070079836A1 (en) * 1999-07-01 2007-04-12 Medtronic Minimed, Inc. Reusable Infusion Site and Method of Using the Same
US7247138B2 (en) * 1999-07-01 2007-07-24 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US20040143173A1 (en) * 1999-07-01 2004-07-22 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US6614521B2 (en) * 1999-08-31 2003-09-02 Cme Telemetrix Inc. Device for verifying the accuracy of a spectral analyzer
US20020123676A1 (en) * 1999-09-08 2002-09-05 Ulrich Haueter Measuring device for body fluids and infusion set and dialysis probe comprising such a measuring device one
US8668645B2 (en) 2001-01-02 2014-03-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9610034B2 (en) 2001-01-02 2017-04-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9498159B2 (en) 2001-01-02 2016-11-22 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8652043B2 (en) 2001-01-02 2014-02-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9011332B2 (en) 2001-01-02 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8236242B2 (en) 2001-04-02 2012-08-07 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
US8765059B2 (en) 2001-04-02 2014-07-01 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
US7976778B2 (en) 2001-04-02 2011-07-12 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
US8268243B2 (en) 2001-04-02 2012-09-18 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
US9477811B2 (en) 2001-04-02 2016-10-25 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
US7209783B2 (en) 2001-06-15 2007-04-24 Cardiac Pacemakers, Inc. Ablation stent for treating atrial fibrillation
US20030018362A1 (en) * 2001-06-15 2003-01-23 Chris Fellows Ablation stent for treating atrial fibrillation
US7044911B2 (en) * 2001-06-29 2006-05-16 Philometron, Inc. Gateway platform for biological monitoring and delivery of therapeutic compounds
WO2003049592A3 (en) * 2001-06-29 2003-07-31 Philometron Inc Gateway platform for biological monitoring and delivery of therapeutic compounds
US8632463B2 (en) 2001-06-29 2014-01-21 Philometron, Inc. Gateway platform for biological monitoring and delivery of therapeutic compounds
US10039480B2 (en) 2001-07-27 2018-08-07 Dexcom, Inc. Membrane for use with implantable devices
US8840552B2 (en) 2001-07-27 2014-09-23 Dexcom, Inc. Membrane for use with implantable devices
US9328371B2 (en) 2001-07-27 2016-05-03 Dexcom, Inc. Sensor head for use with implantable devices
US9532741B2 (en) 2001-07-27 2017-01-03 Dexcom, Inc. Membrane for use with implantable devices
US8509871B2 (en) 2001-07-27 2013-08-13 Dexcom, Inc. Sensor head for use with implantable devices
US9804114B2 (en) 2001-07-27 2017-10-31 Dexcom, Inc. Sensor head for use with implantable devices
US20050004526A1 (en) * 2001-08-31 2005-01-06 Andreas Reinemann Implant with surface structure
US7766881B2 (en) * 2001-08-31 2010-08-03 Roche Diagnostics International Ag Implant with surface structure
US7236821B2 (en) 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
US9801574B2 (en) 2002-05-22 2017-10-31 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US8050731B2 (en) 2002-05-22 2011-11-01 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US8865249B2 (en) 2002-05-22 2014-10-21 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US11020026B2 (en) 2002-05-22 2021-06-01 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US8543184B2 (en) 2002-05-22 2013-09-24 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US9179869B2 (en) 2002-05-22 2015-11-10 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US10154807B2 (en) 2002-05-22 2018-12-18 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US8064977B2 (en) 2002-05-22 2011-11-22 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US10052051B2 (en) 2002-05-22 2018-08-21 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US9549693B2 (en) 2002-05-22 2017-01-24 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US8053018B2 (en) 2002-05-22 2011-11-08 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US8275456B2 (en) 2002-11-12 2012-09-25 Cardiac Pacemakers, Inc. Implantable device for delivering cardiac drug therapy
US7881763B2 (en) 2003-04-04 2011-02-01 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US7875293B2 (en) 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US8118877B2 (en) 2003-05-21 2012-02-21 Dexcom, Inc. Porous membranes for use with implantable devices
US9763609B2 (en) 2003-07-25 2017-09-19 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
USRE43399E1 (en) 2003-07-25 2012-05-22 Dexcom, Inc. Electrode systems for electrochemical sensors
US7761130B2 (en) 2003-07-25 2010-07-20 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7896809B2 (en) 2003-07-25 2011-03-01 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US10376143B2 (en) 2003-07-25 2019-08-13 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8676287B2 (en) 2003-08-01 2014-03-18 Dexcom, Inc. System and methods for processing analyte sensor data
US8394021B2 (en) 2003-08-01 2013-03-12 Dexcom, Inc. System and methods for processing analyte sensor data
US8986209B2 (en) 2003-08-01 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
US8915849B2 (en) 2003-08-01 2014-12-23 Dexcom, Inc. Transcutaneous analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8788007B2 (en) 2003-08-01 2014-07-22 Dexcom, Inc. Transcutaneous analyte sensor
US8788006B2 (en) 2003-08-01 2014-07-22 Dexcom, Inc. System and methods for processing analyte sensor data
US8052601B2 (en) 2003-08-01 2011-11-08 Dexcom, Inc. System and methods for processing analyte sensor data
US8700117B2 (en) 2003-08-01 2014-04-15 Dexcom, Inc. System and methods for processing analyte sensor data
US8000901B2 (en) 2003-08-01 2011-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US8442610B2 (en) 2003-08-01 2013-05-14 Dexcom, Inc. System and methods for processing analyte sensor data
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US8622905B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. System and methods for processing analyte sensor data
US8016783B2 (en) 2003-08-21 2011-09-13 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
US8911369B2 (en) 2003-12-05 2014-12-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US10299712B2 (en) 2003-12-05 2019-05-28 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US10188333B2 (en) 2003-12-05 2019-01-29 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US8160671B2 (en) 2003-12-05 2012-04-17 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US8483793B2 (en) 2003-12-05 2013-07-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11020031B1 (en) 2003-12-05 2021-06-01 Dexcom, Inc. Analyte sensor
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US8249684B2 (en) 2003-12-05 2012-08-21 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
USRE44695E1 (en) 2003-12-05 2014-01-07 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8428678B2 (en) 2003-12-05 2013-04-23 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US8929968B2 (en) 2003-12-05 2015-01-06 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US9579053B2 (en) 2003-12-05 2017-02-28 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7364592B2 (en) 2004-02-12 2008-04-29 Dexcom, Inc. Biointerface membrane with macro-and micro-architecture
US20050251083A1 (en) * 2004-02-12 2005-11-10 Victoria Carr-Brendel Biointerface with macro-and micro-architecture
US10835672B2 (en) 2004-02-26 2020-11-17 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US11246990B2 (en) 2004-02-26 2022-02-15 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US10966609B2 (en) 2004-02-26 2021-04-06 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US20050197653A1 (en) * 2004-03-02 2005-09-08 Sniegowski Jeffry J. Filter assembly with microfabricated filter element
US9833143B2 (en) 2004-05-03 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US8792955B2 (en) 2004-05-03 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US10327638B2 (en) 2004-05-03 2019-06-25 Dexcom, Inc. Transcutaneous analyte sensor
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US8229534B2 (en) 2004-07-13 2012-07-24 Dexcom, Inc. Transcutaneous analyte sensor
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US9775543B2 (en) 2004-07-13 2017-10-03 Dexcom, Inc. Transcutaneous analyte sensor
US8690775B2 (en) 2004-07-13 2014-04-08 Dexcom, Inc. Transcutaneous analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US10722152B2 (en) 2004-07-13 2020-07-28 Dexcom, Inc. Analyte sensor
US9668677B2 (en) 2004-07-13 2017-06-06 Dexcom, Inc. Analyte sensor
US8721545B2 (en) 2004-07-13 2014-05-13 Dexcom, Inc. Transcutaneous analyte sensor
US7654956B2 (en) 2004-07-13 2010-02-02 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US9610031B2 (en) 2004-07-13 2017-04-04 Dexcom, Inc. Transcutaneous analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US8750955B2 (en) 2004-07-13 2014-06-10 Dexcom, Inc. Analyte sensor
US8483791B2 (en) 2004-07-13 2013-07-09 Dexcom, Inc. Transcutaneous analyte sensor
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US9814414B2 (en) 2004-07-13 2017-11-14 Dexcom, Inc. Transcutaneous analyte sensor
US8475373B2 (en) 2004-07-13 2013-07-02 Dexcom, Inc. Transcutaneous analyte sensor
US8663109B2 (en) 2004-07-13 2014-03-04 Dexcom, Inc. Transcutaneous analyte sensor
US8792953B2 (en) 2004-07-13 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US9833176B2 (en) 2004-07-13 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US10799159B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US8801611B2 (en) 2004-07-13 2014-08-12 Dexcom, Inc. Transcutaneous analyte sensor
US8812072B2 (en) 2004-07-13 2014-08-19 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US11064917B2 (en) 2004-07-13 2021-07-20 Dexcom, Inc. Analyte sensor
US10799158B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US7899511B2 (en) 2004-07-13 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US10813576B2 (en) 2004-07-13 2020-10-27 Dexcom, Inc. Analyte sensor
US7949381B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
US7946984B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
US11045120B2 (en) 2004-07-13 2021-06-29 Dexcom, Inc. Analyte sensor
US11026605B1 (en) 2004-07-13 2021-06-08 Dexcom, Inc. Analyte sensor
US7905833B2 (en) 2004-07-13 2011-03-15 Dexcom, Inc. Transcutaneous analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10022078B2 (en) 2004-07-13 2018-07-17 Dexcom, Inc. Analyte sensor
US9078626B2 (en) 2004-07-13 2015-07-14 Dexcom, Inc. Transcutaneous analyte sensor
US10709363B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8515519B2 (en) 2004-07-13 2013-08-20 Dexcom, Inc. Transcutaneous analyte sensor
US8615282B2 (en) 2004-07-13 2013-12-24 Dexcom, Inc. Analyte sensor
US8313434B2 (en) 2004-07-13 2012-11-20 Dexcom, Inc. Analyte sensor inserter system
US10524703B2 (en) 2004-07-13 2020-01-07 Dexcom, Inc. Transcutaneous analyte sensor
US10993642B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10827956B2 (en) 2004-07-13 2020-11-10 Dexcom, Inc. Analyte sensor
US11883164B2 (en) 2004-07-13 2024-01-30 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8280475B2 (en) 2004-07-13 2012-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US10993641B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10980452B2 (en) 2004-07-13 2021-04-20 Dexcom, Inc. Analyte sensor
US10918314B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US9044199B2 (en) 2004-07-13 2015-06-02 Dexcom, Inc. Transcutaneous analyte sensor
US10709362B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10918315B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US9055901B2 (en) 2004-07-13 2015-06-16 Dexcom, Inc. Transcutaneous analyte sensor
US10918313B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US8457708B2 (en) 2004-07-13 2013-06-04 Dexcom, Inc. Transcutaneous analyte sensor
US20060020192A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US10314525B2 (en) 2004-07-13 2019-06-11 Dexcom, Inc. Analyte sensor
US10932700B2 (en) 2004-07-13 2021-03-02 Dexcom, Inc. Analyte sensor
US20060030790A1 (en) * 2004-08-06 2006-02-09 Braig James R Sample element with barrier material and vacuum
US7828711B2 (en) 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US20060041318A1 (en) * 2004-08-19 2006-02-23 Shannon Donald T Laminar skin-bone fixation transcutaneous implant and method for use thereof
US8805492B2 (en) 2004-08-20 2014-08-12 Cardiac Pacemakers, Inc. Method and apparatus for delivering combined electrical and drug therapies
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US20120281218A1 (en) * 2005-01-24 2012-11-08 The Board Of Trustees Of The Leland Stanford Junior University Optical analysis system and approach therefor
US9839361B2 (en) 2005-01-24 2017-12-12 The Board Of Trustees Of The Leland Stanford Junior University Optical analysis system and approach therefor
US9161694B2 (en) * 2005-01-24 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Optical analysis system and approach therefor
US10918317B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10709364B2 (en) 2005-03-10 2020-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10743801B2 (en) 2005-03-10 2020-08-18 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918318B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10716498B2 (en) 2005-03-10 2020-07-21 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10898114B2 (en) 2005-03-10 2021-01-26 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10856787B2 (en) 2005-03-10 2020-12-08 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9220449B2 (en) 2005-03-10 2015-12-29 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610102B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. Transcutaneous analyte sensor
US10617336B2 (en) 2005-03-10 2020-04-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9314196B2 (en) 2005-03-10 2016-04-19 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10624539B2 (en) 2005-03-10 2020-04-21 Dexcom, Inc. Transcutaneous analyte sensor
US11000213B2 (en) 2005-03-10 2021-05-11 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9078608B2 (en) 2005-03-10 2015-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8560037B2 (en) 2005-03-10 2013-10-15 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8579816B2 (en) 2005-03-10 2013-11-12 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610137B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8611978B2 (en) 2005-03-10 2013-12-17 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918316B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9918668B2 (en) 2005-03-10 2018-03-20 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10925524B2 (en) 2005-03-10 2021-02-23 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610135B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11051726B2 (en) 2005-03-10 2021-07-06 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor
US10610103B2 (en) 2005-06-21 2020-04-07 Dexcom, Inc. Transcutaneous analyte sensor
US10709332B2 (en) 2005-06-21 2020-07-14 Dexcom, Inc. Transcutaneous analyte sensor
US20100145281A1 (en) * 2005-07-06 2010-06-10 Strategic Applications, Inc. Harness Interface Conduit, Tether Line, and Swivel for Use in Animals
US20070006820A1 (en) * 2005-07-06 2007-01-11 Steven Denault Harness interface conduit, tether line, and swivel for use in animals
US7665424B2 (en) * 2005-07-06 2010-02-23 Strategic Applications, Inc. Harness interface conduit, tether line, and swivel for use in animals
US8660648B2 (en) 2005-10-24 2014-02-25 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US9326716B2 (en) 2005-11-01 2016-05-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11363975B2 (en) 2005-11-01 2022-06-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10952652B2 (en) 2005-11-01 2021-03-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10231654B2 (en) 2005-11-01 2019-03-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8920319B2 (en) 2005-11-01 2014-12-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11911151B1 (en) 2005-11-01 2024-02-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11103165B2 (en) 2005-11-01 2021-08-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8915850B2 (en) 2005-11-01 2014-12-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11399748B2 (en) 2005-11-01 2022-08-02 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9078607B2 (en) 2005-11-01 2015-07-14 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11272867B2 (en) 2005-11-01 2022-03-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10201301B2 (en) 2005-11-01 2019-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11596332B2 (en) 2006-01-17 2023-03-07 Dexcom, Inc. Low oxygen in vivo analyte sensor
US9757061B2 (en) 2006-01-17 2017-09-12 Dexcom, Inc. Low oxygen in vivo analyte sensor
US10265000B2 (en) 2006-01-17 2019-04-23 Dexcom, Inc. Low oxygen in vivo analyte sensor
US11191458B2 (en) 2006-01-17 2021-12-07 Dexcom, Inc. Low oxygen in vivo analyte sensor
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
US9724028B2 (en) 2006-02-22 2017-08-08 Dexcom, Inc. Analyte sensor
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US10349873B2 (en) 2006-10-04 2019-07-16 Dexcom, Inc. Analyte sensor
US7831287B2 (en) 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11399745B2 (en) 2006-10-04 2022-08-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11382539B2 (en) 2006-10-04 2022-07-12 Dexcom, Inc. Analyte sensor
US9451908B2 (en) 2006-10-04 2016-09-27 Dexcom, Inc. Analyte sensor
US10136844B2 (en) 2006-10-04 2018-11-27 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US9504413B2 (en) 2006-10-04 2016-11-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US10791928B2 (en) 2007-05-18 2020-10-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8562558B2 (en) 2007-06-08 2013-10-22 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US9741139B2 (en) 2007-06-08 2017-08-22 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US10403012B2 (en) 2007-06-08 2019-09-03 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US11373347B2 (en) 2007-06-08 2022-06-28 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US9451910B2 (en) 2007-09-13 2016-09-27 Dexcom, Inc. Transcutaneous analyte sensor
US9668682B2 (en) 2007-09-13 2017-06-06 Dexcom, Inc. Transcutaneous analyte sensor
US11672422B2 (en) 2007-09-13 2023-06-13 Dexcom, Inc. Transcutaneous analyte sensor
US11160926B1 (en) 2007-10-09 2021-11-02 Dexcom, Inc. Pre-connected analyte sensors
US11744943B2 (en) 2007-10-09 2023-09-05 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US11272869B2 (en) 2007-10-25 2022-03-15 Dexcom, Inc. Systems and methods for processing sensor data
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US10182751B2 (en) 2007-10-25 2019-01-22 Dexcom, Inc. Systems and methods for processing sensor data
US9717449B2 (en) 2007-10-25 2017-08-01 Dexcom, Inc. Systems and methods for processing sensor data
US9440058B2 (en) * 2007-12-17 2016-09-13 Cook Medical Technologies, LLC Device for enabling repeated access to a vessel
US20090157014A1 (en) * 2007-12-17 2009-06-18 William Cook Europe Aps Device for enabling repeated access to a vessel
US9694165B2 (en) * 2008-01-28 2017-07-04 Peter Mats Forsell Implantable drainage device
US20150157836A1 (en) * 2008-01-28 2015-06-11 Peter Mats Forsell Implantable drainage device
US20090205647A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Pneumostoma management system having a cosmetic and/or protective cover
US8464708B2 (en) * 2008-02-19 2013-06-18 Portaero, Inc. Pneumostoma management system having a cosmetic and/or protective cover
US10602968B2 (en) 2008-03-25 2020-03-31 Dexcom, Inc. Analyte sensor
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US11896374B2 (en) 2008-03-25 2024-02-13 Dexcom, Inc. Analyte sensor
US10143410B2 (en) 2008-03-28 2018-12-04 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9572523B2 (en) 2008-03-28 2017-02-21 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9173607B2 (en) 2008-03-28 2015-11-03 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9173606B2 (en) 2008-03-28 2015-11-03 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8954128B2 (en) 2008-03-28 2015-02-10 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9549699B2 (en) 2008-03-28 2017-01-24 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9566026B2 (en) 2008-03-28 2017-02-14 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11147483B2 (en) 2008-03-28 2021-10-19 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9693721B2 (en) 2008-03-28 2017-07-04 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8398654B2 (en) 2008-04-17 2013-03-19 Allergan, Inc. Implantable access port device and attachment system
US9023062B2 (en) 2008-04-17 2015-05-05 Apollo Endosurgery, Inc. Implantable access port device and attachment system
US8409221B2 (en) 2008-04-17 2013-04-02 Allergan, Inc. Implantable access port device having a safety cap
US9023063B2 (en) 2008-04-17 2015-05-05 Apollo Endosurgery, Inc. Implantable access port device having a safety cap
US8690769B2 (en) 2008-04-21 2014-04-08 Philometron, Inc. Metabolic energy monitoring system
US20180214059A1 (en) * 2008-05-30 2018-08-02 Intuity Medical, Inc. Body fluid sampling device - sampling site interface
US11045125B2 (en) * 2008-05-30 2021-06-29 Intuity Medical, Inc. Body fluid sampling device-sampling site interface
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US9173903B2 (en) 2009-08-17 2015-11-03 Ashok K. Singh Fluid associated with adult stem cells for medical, cosmetic, and veterinary use
WO2011022045A3 (en) * 2009-08-17 2011-04-14 Singh Ashok K Apparatus and process for generating and harvesting adult stem cells and fluid associated with it from skin and omentum for medical, cosmetic, and veterinary use
US20110038903A1 (en) * 2009-08-17 2011-02-17 Singh Ashok K Apparatus and Process for Generating and Harvesting Adult Stem Cells and Fluid Associated with it from Skin and Omentum for Medical, Cosmetic, and Veterinary Use
US8708979B2 (en) 2009-08-26 2014-04-29 Apollo Endosurgery, Inc. Implantable coupling device
US8506532B2 (en) 2009-08-26 2013-08-13 Allergan, Inc. System including access port and applicator tool
US8715158B2 (en) 2009-08-26 2014-05-06 Apollo Endosurgery, Inc. Implantable bottom exit port
US9167997B2 (en) * 2009-11-16 2015-10-27 Maquet Critical Care Ab Self-flowing measuring system
US20120289795A1 (en) * 2009-11-16 2012-11-15 Maquet Critical Care Ab Self-Flowing Measuring System
US8882728B2 (en) 2010-02-10 2014-11-11 Apollo Endosurgery, Inc. Implantable injection port
US9075910B2 (en) 2010-03-11 2015-07-07 Philometron, Inc. Physiological monitor system for determining medication delivery and outcome
US8992415B2 (en) 2010-04-30 2015-03-31 Apollo Endosurgery, Inc. Implantable device to protect tubing from puncture
US9125718B2 (en) 2010-04-30 2015-09-08 Apollo Endosurgery, Inc. Electronically enhanced access port for a fluid filled implant
US9192501B2 (en) 2010-04-30 2015-11-24 Apollo Endosurgery, Inc. Remotely powered remotely adjustable gastric band system
US9241819B2 (en) 2010-04-30 2016-01-26 Apollo Endosurgery, Inc. Implantable device to protect tubing from puncture
US20130066171A1 (en) * 2010-05-06 2013-03-14 Roche Diagnostics Operations, Inc. Lancet Magazine and Method for the Production Thereof
US10524709B2 (en) * 2010-05-06 2020-01-07 Roche Diabetes Care, Inc. Lancet magazine and method for the production thereof
US8905962B2 (en) * 2010-07-02 2014-12-09 Nikkiso Co., Ltd. Artificial blood vessel and access port of artificial blood vessel
TWI455707B (en) * 2010-07-02 2014-10-11 Nikkiso Co Ltd Access to artificial blood vessels and artificial blood vessels埠
US20130103136A1 (en) * 2010-07-02 2013-04-25 Nikkiso Co., Ltd. Artificial blood vessel and access port of artificial blood vessel
CN103002942B (en) * 2010-07-02 2015-06-03 日机装株式会社 Artificial blood vessel and access port of artificial blood vessel
EP2505218A4 (en) * 2010-07-02 2017-11-01 Nikkiso Co., Ltd. Artificial blood vessel and access port of artificial blood vessel
CN103211662A (en) * 2010-07-02 2013-07-24 日机装株式会社 Artificial blood vessel
CN103002942A (en) * 2010-07-02 2013-03-27 日机装株式会社 Artificial blood vessel and access port of artificial blood vessel
US8905916B2 (en) 2010-08-16 2014-12-09 Apollo Endosurgery, Inc. Implantable access port system
US11285258B2 (en) 2010-08-25 2022-03-29 Medtronic, Inc. Fluid delivery device refill access
US9737660B2 (en) 2010-08-25 2017-08-22 Medtronic, Inc. Drug infusion device with controllable valve
US10143796B2 (en) * 2010-08-25 2018-12-04 Medtronic, Inc. Fluid delivery device refill access
US20120053562A1 (en) * 2010-08-25 2012-03-01 Medtronic, Inc. Fluid delivery device refill access
US8882655B2 (en) 2010-09-14 2014-11-11 Apollo Endosurgery, Inc. Implantable access port system
US8821373B2 (en) 2011-05-10 2014-09-02 Apollo Endosurgery, Inc. Directionless (orientation independent) needle injection port
US9615759B2 (en) * 2011-07-12 2017-04-11 Bard Access Systems, Inc. Devices and methods for ECG guided vascular access
US20130018248A1 (en) * 2011-07-12 2013-01-17 Romedex International Srl Devices and methods for ECG guided vascular access
US8801597B2 (en) 2011-08-25 2014-08-12 Apollo Endosurgery, Inc. Implantable access port with mesh attachment rivets
US9199069B2 (en) 2011-10-20 2015-12-01 Apollo Endosurgery, Inc. Implantable injection port
US8858421B2 (en) 2011-11-15 2014-10-14 Apollo Endosurgery, Inc. Interior needle stick guard stems for tubes
US9089395B2 (en) 2011-11-16 2015-07-28 Appolo Endosurgery, Inc. Pre-loaded septum for use with an access port
US20150297873A1 (en) * 2012-08-22 2015-10-22 Clemson University Research Foundation Percutaneous tube stabilization device
US11420033B2 (en) 2013-01-23 2022-08-23 C. R. Bard, Inc. Low-profile single and dual vascular access device
US10463845B2 (en) 2013-01-23 2019-11-05 C.R. Bard, Inc. Low-profile access port
US11464960B2 (en) 2013-01-23 2022-10-11 C. R. Bard, Inc. Low-profile single and dual vascular access device
US20150266026A1 (en) * 2014-03-18 2015-09-24 Sony Corporation Plate-like member for pipette tips, pipette tip, liquid agitation kit and liquid agitation apparatus
US11045633B2 (en) * 2014-04-10 2021-06-29 University Health Network Cannula for connecting medical devices to biological systems
US20170036006A1 (en) * 2014-04-10 2017-02-09 University Health Network Cannula for connecting medical devices to biological systems
US9814413B2 (en) * 2014-07-24 2017-11-14 Thomas Jefferson University Long-term implantable monitoring system and methods of use
US20160022180A1 (en) * 2014-07-24 2016-01-28 Thomas Jefferson University Long-term implantable monitoring system & methods of use
US10682079B2 (en) 2014-07-24 2020-06-16 Thomas Jefferson University Long-term implantable monitoring system and methods of use
USD885557S1 (en) 2017-09-06 2020-05-26 C. R. Bard, Inc. Implantable apheresis port
USD870264S1 (en) 2017-09-06 2019-12-17 C. R. Bard, Inc. Implantable apheresis port
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
US11706876B2 (en) 2017-10-24 2023-07-18 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
CN112040839A (en) * 2018-02-09 2020-12-04 W.L.戈尔及同仁股份有限公司 Implantable access chamber and associated methods of use
EP3760273A1 (en) * 2019-07-02 2021-01-06 SeraIP AG Implantable skin penetration device

Also Published As

Publication number Publication date
US20020183604A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
US6459917B1 (en) Apparatus for access to interstitial fluid, blood, or blood plasma components
US7166074B2 (en) Reusable analyte sensor site and method of using the same
US6368274B1 (en) Reusable analyte sensor site and method of using the same
US4777953A (en) Capillary filtration and collection method for long-term monitoring of blood constituents
CA2424288C (en) Device and method for obtaining interstitial fluid from a patient for diagnostic tests
US5002054A (en) Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body
CA2787010C (en) Combined sensor and infusion sets
US4854322A (en) Capillary filtration and collection device for long-term monitoring of blood constituents
US6254586B1 (en) Method and kit for supplying a fluid to a subcutaneous placement site
DK2732837T3 (en) Combined sensor and infusion set for use on separate sites
US5951521A (en) Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site
US7041057B1 (en) Tissue interface device
US20090312622A1 (en) Device And Method For Determining A Value Of A Physiological Parameter Of A Body Fluid
US20070004989A1 (en) Device for transdermal sampling
WO2000035530A1 (en) Insertion sets with micro-piercing members for use with medical devices and methods of using the same
WO2006122048A1 (en) Dual insertion set
WO2007054317A1 (en) Determining a value of a physiological parameter
US20080234563A1 (en) Device for and Method of Delivery and Removal of Substances in and From a Tissue or Vessel

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Expired due to failure to pay maintenance fee

Effective date: 20101001